NF Conference

SEPTEMBER 21-24, 2019 HYATT REGENCY SAN FRANCISCO, CA



CONTENTS Table of Contents

Welcome Message	4
Foundation Staff	5
Advisory Boards	6
Funding Opportunities	7
The Friedrich von Recklinghausen Award: NF Tradition and Progress	8
Schedule at a Glance	9
Conference Co-Chairs	10
Keynote Speakers	11
Agenda	13
Participants	20
Conference Venue Floor Plan	25
Local Area Dining Options	26
Acknowledgments	28
Sponsors, Supporters and Exhibitors	29

DOWNLOAD THE 2019 NF CONFERENCE MOBILE APPLICATION

The app is available for iPhone, iPad, Blackberry and Android devices and will enable you to consult the latest news on the event, read about the sessions, network with colleagues, plan your visit, and much more!



Password: nfconference (all lower case)

Dear NF Conference and NF Forum Attendees:

On behalf of the Children's Tumor Foundation, I welcome you to the 2019 NF Conference and NF Forum in beautiful San Francisco, California. It is an honor and inspiration to bring the entire NF community together so that scientists, clinicians, volunteers, donors, families, patients, and CTF staff members can mix and mingle, learn from each other, and make this weekend incredibly special.

If you were to ask me: what would make you the most grateful at this year's NF Conference and Forum? The answer would be very simple: to grow our CTF family even more.

We are tremendously pleased to have as our opening keynote speaker Dr. Stephen Groft, Director of the NIH's Office of Rare Diseases Research – an absolute guru in the rare disease space!

Our dedicated NF Conference Chairs Allan Belzberg, Juha Peltonen and Jill Weimer, together with our conference director Patrice Pancza, were able to attract some indisputable talent this year. It is exciting to note that keynote speakers from outside the NF community will be with us, including Lloyd Minor, MD, Dean of the Stanford University School of Medicine; Allan Basbaum PhD, FRS, Professor and Chair, Department of Anatomy, University of California, San Francisco; and Heike Daldrup-Link, MD, PhD, Department of Radiology, Stanford University. They enthusiastically accepted our request to come to the conference and share their expert views on the fields of cancer, pain, and imaging.

This year's NF Forum will offer an impressive program to educate and empower patients, families, and caregivers. Over the past year, CTF engaged with the European Patient Forum in a project around patient engagement (PARADIGM) and the lead of this project, Mathieu Boudes, PhD, will present at the NF Forum.

The astonishing NF Forum Chairs Dave Viskochil, Andrea Gross, Onno Faber, Maureen Hussey and Jessica Sambalnet, together with our Director of Patient Engagement Traceann Rose, drew wonderful experts, many of them also new to the NF community. Stefan Friedrichsdorf, MD, the Medical Director of the Department of Pain Medicine, Palliative Care and Integrative Medicine at Children's Minnesota, Minneapolis-St. Paul, will present on the important topic of NF and pain. The Forum will also include a panel discussion on drug development that will include a team of industry, medical professionals, and patients.

I truly hope that you will be able to join us at the combined Conference-Forum dinner on Saturday evening, where we are pleased to present a global panel of caregivers and patients who will talk about NF care around the world.

Last but not least, I wish you a few enriching, inspiring, and fun days. Enjoy the company of old friends, make some new friends, and celebrate each other's successes and discoveries. We will build upon the knowledge shared and the collaborations fostered this weekend, because only together can we end NF!

ANNETTE BAKKER President and Chief Scientific Officer

FOUNDATION STAFF

Children's Tumor Foundation

Annette Bakker, PhD - President

Research and Medical Programs

Salvatore La Rosa, PhD - Chief Scientific Officer Melanie Barry - Senior Executive Assistant Vidya Browder, PhD - Basic Science Senior Manager Kate Kelts - Patient Support Coordinator Pamela Knight - Director, Clinical Program Patrice Pancza - Vice President, External Relations Heather Radtke - Clinic and Symposium Senior Manager Traceann Rose - Director, Patient and Volunteer Engagement Dani Williams - External Relations Coordinator

Development

Michele Przypyszny - Chief Advancement Officer Katie Bloom - Director, Major Gifts Allison Cote - Development Manager, Endurance Emily Crabtree -, Director, Development Operations Allyson Douglass - Development Manager, Special Events Angela Dumadag - Senior Development Manager, Lifestyle Barbara Gallagher - Vice President, Field Development Lolita Jerido - Development Manager, Walk Julie Pantoliano - Senior Manager, Youth Programs Kim Robinson - Development Manager, Special Events Connie Sorman - Senior Manager, Stewardship and Volunteer Development Jennifer White - Development Manager, Walk

Finance and Administration

Sarah Bourne - Vice President, Finance Taylor Bertran - Gift Processing Coordinator Monique Boucher - Gift Processing Senior Manager Carey Milligan - Senior Accounting Manager Brandon Weaver-Bey - Gift Processing Coordinator

Marketing and Communications

Simon Vukelj - Chief Marketing Officer Albert Diaz - Director, IT and Salesforce Administration Rebecca Harris - Public Relations Senior Manager Alissa Marks - Marketing Senior Manager Susanne Preinfalk - Design Director Vanessa Younger - Communications Director

CTF BOARD OF DIRECTORS

Executive Members

Richard Horvitz - Chair Tracy Galloway - Vice Chair Randall Stanicky - Treasurer Gabriel Groisman - Secretary Linda Halliday Martin - Chair Emeritus

Board Members

Daniel Altman Amy Boulas Robert Brainin Daniel Gilbert John Golfinos, MD Carol Kalagher Simone Manso Steven L. McKenzie Laura Perfetti Michael Peterson Liz Rodbell Kenneth Rudd Richard Soll Stuart Suna Rachel B. Tiven

Advisory Board Members

Bruce R. Korf, MD, PhD - Chair, Medical Advisory Committee Scott Plotkin, MD, PhD - Chair, Clinical Care Advisory Board Peggy Wallace, PhD - Chair, Research Advisory Board

Volunteer Leadership Council Chair

Renie Moss

Honorary Directors

Suzanne Earle Michie Stovall O'Day Alan Robbins, MD Carolyn E. Setlow Nate Walker Ed Stern - Pro Bono Counsel Allan Rubenstein, MD - Director of Medical Affairs Emeritus



ADVISORY BOARDS

Children's Tumor Foundation Advisory Boards

Clinical Care Advisory Board

Scott Plotkin, MD, PhD (Chair), Massachusetts General Hospital Oliver Adunka, MD, Ohio State University Gary Brenner, MD, PhD, Massachusetts General Hospital Jan Friedman, MD, PhD, University of British Columbia Bonnie Klein-Tasman, PhD, University of Wisconsin Milwaukee Laura Klesse, MD, PhD, UT Southwestern Medical Center Jennifer Janusz, PsyD, ABPP-Cn, Children's Hospital Colorado Justin Jordan, MD, MPH, Massachusetts General Hospital Tena Rosser, MD, Children's Hospital of Los Angeles Elizabeth Schorry, MD, Cincinnati Children's Hospital Pamela Trapane, MD, UF Health Jacksonville Nicole Ullrich, MD, PhD, Boston Children's Hospital David Viskochil, MD, PhD (Chair, Emeritus), University of Utah Kaleb Yohay, MD, NYU Langone Medical Center CTF Staff: Pamela Knight and Heather Radtke

Medical Advisory Committee

Bruce Korf, MD, PhD (Chair), Alabama Richard Horvitz, CTF Chair of the BOD Annette Bakker, PhD, CTF President Salvatore La Rosa, PhD CTF Chief Scientific Officer Margaret (Peggy) Wallace, PhD, University of Florida Andrea McClatchey, PhD, Massachusetts General Hospital Michael Fisher, MD, CHoP Jaishri Blakeley, MD, Johns Hopkins University David Miller, MD, PhD, Boston Children's Hospital Yoori Kim, PhD, GFF Scientific Officer Scott Plotkin, MD, PhD, Massachusetts General Hospital Nader Futouhi, PhD, TB Alliance Chief Scientific Officer Ed Stern, ESQ, CTF Member of BOD Stuart Suna, CTF Member of BOD Tracy Galloway, CTF Vice-chair of BOD Suzanne Earle, CTF Member of BOD Marco Nievo, PhD, Patent Attorney D. Wade Clapp, MD, Indiana University Brigitte Wideman, MD, National Cancer Institute Dave Viskochil, MD, PhD, University of Utah

Research Advisory Committee Program Chairs/Core Committee

Margaret Wallace, PhD Andrea McClatchey, PhD Cynthia Hingtgen, PhD Cristina Fernandez-Valle, PhD Bruce Korf, MD, PhD Nader Fotouhi, PhD Scott Plotkin, MD, PhD David Viskochil, MD, PhD

CHILDREN'S TUMOR FOUNDATION FUNDING OPPORTUNITIES IN 2020

YOUNG INVESTIGATOR AWARDS

The Children's Tumor Foundation has always striven to fund innovative NF research through its investigator-initiated award programs, namely the Young Investigator Award (YIA), Drug Discovery Initiative (DDI), Drug Discovery Initiative Registered Reports (DDIRR), and Clinical Research Award (CRA). Towards this, we are very happy to announce that we have significantly increased the **amount of funding for the YIA program for the upcoming 2020 cycle.** We expect that this increased allocation of funds will allow us to support several more early-stage researchers than we could in the recent past.

The YIA program will once again be expanded to include **all manifestations of all types of NF (NF1, NF2, schwannomatosis).** Furthermore, a subset of the available funds will be dedicated exclusively to funding NF2 and schwannomatosis-focused studies, and such proposals will be evaluated separate from the NF1-focused proposals to ensure that at least a minimum number of NF2/ schwannomatosis studies can be initiated. We hope that these changes will encourage all early-stage NF researchers, especially those interested in NF2 and schwannomatosis, to consider applying to the YIA program!

AWARD AMOUNTS:

Award amounts vary depending on pre-doc or post-doc status of the applicant and level of training. Please refer to our website https://www.ctf.org/research/awards-applications for more information.

IMPORTANT DATES TO NOTE

- Monday, Dec. 9, 2019 YIA Letter of Intent (LOI) form posted on ctf.org
- Friday, Jan. 3, 2020 YIA LOI's due by 5:00 pm EST
- Friday, Jan. 24, 2020 YIA invitation to full application
- Friday, Mar. 6, 2020 Full applications due by 5:00 pm EST
- Week of May 18, 2020 YIA decision notifications

DRUG DISCOVERY INITIATIVE REGISTERED REPORTS (DDIRR)

DDIRR Awards is a funder-publisher partnership that integrates the Registered Reports model in the grant application process. This model will allow for more rigorous, reproducible and transparent science, guaranteeing its awaradees with an in-principle acceptance (IPA) to publication in the journal PLOS ONE, regardless of study outcome.

AWARD AMOUNTS:

up to \$40,000 for in-vitro studies up to \$85,000 for in-vivo studies

IMPORTANT DATES TO NOTE

- · Monday, Sept. 23, 2019 Letter of Intent (LOI) form posted on ctf.org
- Monday, Oct. 21, 2019 LOI's due by 5:00pm EST
- Monday, Nov. 18, 2019 Invitation to full application
- Monday, Dec. 16, 2019 Full proposals due by 5:00pm EST
- March, 2020 Decision Notifications

CLINICAL RESEARCH AWARDS

To accelerate NF research, CTF launched the Clinical Research Award (CRA) program in 2007 to support early stage pilot clinical trials of candidate therapeutics or interventions for treatment of manifestations of NF1, NF2 and schwannomatosis. In addition, these awards support innovative clinical trial enabling studies.

AWARD AMOUNTS:

Funding of up to \$150,000 is offered for these two-year awards.

IMPORTANT DATES TO NOTE

The next award cycle for CRAs will begin in the fall of 2020. Exact dates for submission of application materials will be provided on the ctf.org website shortly.

Please connect with any of the CTF staff for any questions. We look forward to receiving your applications!



The Friedrich von Recklinghausen Award: Neurofibromatosis Tradition and Progress

The Children's Tumor Foundation's Friedrich von Recklinghausen Award is given to individuals in the professional neurofibromatosis community who have made significant contributions to neurofibromatosis research or clinical care. It is named after Friedrich Daniel von Recklinghausen (1833-1910), the German physician who first described 'von Recklinghausen's disease' – what we now know as neurofibromatosis type 1.

2019 Friedrich von Recklinghausen Award Recipient



It is with great pleasure that the Children's Tumor Foundation announces the 2019 recipient of the Friedrich von Recklinghausen Award, Scott Plotkin, MD, PhD, Director of the Family Center for Neurofibromatosis at Massachusetts General Hospital and a Professor of Neurology at Harvard Medical School. This von Recklinghausen award marks the 10-year anniversary of the landmark study establishing the efficacy of bevacizumab for treatment in NF2, led by Dr. Plotkin and published in the New England Journal of Medicine in 2009. Dr. Plotkin has continued to improve treatment of patients with NF2 as an investigator on subsequent clinical trials of bevacizumab and other candidate therapeutics; as a co-PI of the Synodos for NF2 drug discovery program; and as co-founder of NF2 Therapeutics, Inc. Dr. Plotkin has also made major contributions to NF clinical trials as founder and Chair of the Director's Council for the Response Endpoints in Neurofibromatosis and Schwannomatosis (REINS) International Collaboration. Launched at the 2011 CTF NF Conference, REINS now consists of 150+ clinicals, researchers, and patient representatives working across 8 topical groups to standardize and improve clinical outcome measures for use in NF clinical trials.

Dr. Plotkin has demonstrated consistent leadership in the field through his service in numerous committees and conferences; he currently serves as chair of the CTF Clinical Care Advisory Board and co-chair of the International Collaboration for Revision of Diagnostic Criteria for Neurofibromatosis. Finally, this award recognizes the outstanding contributions Dr. Plotkin has made in mentoring new NF clinicians and researchers, many of whom have gone on to receive funding for new lines of NF research from CTF, the DOD, and other agencies.

The following are the most recent recipients of the Award:

Please join us in congratulating Dr. Plotkin for this well-deserved award!



2008 Vincent 'Vic' Riccardi, MD The Neurofibromatosis Institute

2014

Gareth Evans, MD

St. Mary's Hospital,

University of Manchester, UK



2009 Luis Parada, PhD University of Texas Southwestern



2015 Eric Legius, MD, PhD University of Leuven, Belgium



2010 Nancy Ratner, PhD Cincinnati Children's Hospital Medical Center



2016 David Viskochil, MD, PhD University of Utah



2012 David Gutmann, MD, PhD Washington University



2017 Karen Cichowski, PhD Harvard Medical School



2013 Brigitte Widemann, MD National Cancer Institute




2018 Ludwine Messiaen, PhD University of Alabama at Birmingham

SCHEDULE

Schedule At-A-Glance

	TIME		EVENT	LOCATION
~ 0	5:00 PM	8:00 PM	Registration	Grand Ballroom Foyer
FRI 9/20	5:00 PM	10:00 PM	Poster Setup	Pacific H-O
	7:00 AM	5:00 PM	Registration	Grand Ballroom Foyer
	7:30 AM	12:00 PM	CLINICAL CARE SYMPOSIUM	Grand Ballroom
.	12:45 PM	1:00 PM	CONFERENCE KICK-OFF	Grand Ballroom
Saturday September 21	1:00 PM	2:00 PM	KEYNOTE 1: From Patients to Patients – And a Whole Lot In-Between	Grand Ballroom
BEF	2:00 PM	4:00 PM	SESSION 1: Natural History of Neurofibromatosis	Grand Ballroom
EME	4:00 PM	4:30 PM	Break	Grand Ballroom Foyer
SA PT	4:30 PM	5:35 PM	SESSION 2: Psychosocial Issues of the NF Patient	Grand Ballroom
SE	5:30 PM	6:30 PM	Mentoring Session: "Speed-Dating with the Experts"	Seacliff AB
	6:30 PM	7:30 PM	Reception and Special Poster Session for NF Forum Attendees - All Welcome	Pacific H-O
	7:45 PM	9:45 PM	Welcome Dinner for NF Forum and NF Conference Attendees	Grand Ballroom
	6:45 AM	7:45 AM	NFCN Clinic Coordinator Breakfast (By Invitation Only)	Seacliff C
	6:45 AM	7:45 AM	Mentoring Breakfast (RSVP Required)	Seacliff AB
	7:00 AM	5:00 PM	Registration	Grand Ballroom Foyer
	8:00 AM	9:00 AM	KEYNOTE 2: The Precision Health Future: Predicting, Preventing and Curing Cancer	Grand Ballroom
2	9:00 AM	12:00 PM	SESSION 3: Cancer	Grand Ballroom
, 3 22	10:45 AM	12:00 PM	SESSION 3B (Concurrent): Mechanisms of NF2 Loss-Driven Tumorigenesis	Seacliff AB
BEI	12:00 PM	12:45 PM	Lunch	Atrium
SUNDAY September	12:45 PM	1:45 PM	KEYNOTE 3: Whole Body Imaging of Children with Cancer	Grand Ballroom
S EPT S	1:45 PM	3:15 PM	SESSION 4: Diagnostics and Imaging	Grand Ballroom
SI	3:10 PM	3:40 PM	Break	Grand Ballroom Foyer
	3:40 PM	4:40 PM	SESSION 4: Diagnostics and Imaging (Part 2)	Grand Ballroom
	4:45 PM	5:05 PM	Poster Advertisements - Basic Science & Clinical Science	Grand Ballroom
	5:05 PM	7:05 PM	Poster Session - Basic Science & Clinical Science	Pacific H-O
	7:00 PM	10:00 PM	REINS Meeting	Marina Room
	6:45 AM	7:45 AM	Breakfast	Atrium
	7:00 AM	7:55 AM	Funding Opportunities Breakfast (RSVP Required)	Seacliff A
	8:00 AM	9:00 AM	KEYNOTE 4: Recent Advances in Neurobiology and Management of Neuropathic Pain	Grand Ballroom
	9:00 AM	11:00 AM	SESSION 5: Pain and Itch	Grand Ballroom
23	11:00 AM	12:00 PM	SESSION 6: Metabolic Rewiring in NF2 Mutant Tumors	Grand Ballroom
AV EB	12:00 PM	1:00 PM	Lunch on Your Own	
ME	12:00 PM	1:00 PM	Clinical Care Advisory Board Lunch (By Invitation Only)	Seacliff C
PTE	1:00 PM	3:00 PM	SESSION 7A (Concurrent): Cutaneous Neurofibromas – Bench to Bedside	Seacliff AB
SEPTI	2:00 PM	3:00 PM	SESSION 7B (Concurrent): Genetics of NF2 and Schwannomatosis	Seacliff AB
	3:00 PM	3:30 PM	Break	Grand Ballroom Foyer
	3:30 PM	5:00 PM	SESSION 8: Targeted Gene Editing and Gene Therapy for Neurofibromatosis	Grand Ballroom
	5:15 PM	7:15 PM	SESSION 9A (Concurrent): Basic Science Platform Presentations	Seacliff AB
	5:15 PM	7:15 PM	SESSION 9B (Concurrent): Clinical Science Platform Presentations	Grand Ballroom
	7:00 AM	8:00 AM	Breakfast on Your Own	
	8:15 AM	9:00 AM	KEYNOTE 5: Perspectives of a "Long-Term" Recklinologist Focusing on the Future	Grand Ballroom
, 24	9:00 AM	10:00 AM	Oral Poster Presentations & Awards	Grand Ballroom
TUESDAY SEPTEMBER (10:00 AM	11:30 AM	SESSION 10: Animal Models	Grand Ballroom
ES	11:30 AM	11:45 AM	Break	Grand Ballroom Foyer
D E	11:45 AM	12:45 PM	SESSION 11: Second NF Hackathon Outcome	Grand Ballroom
SE	12:45 PM	1:05 PM	SESSION 12: Consortia Update	Grand Ballroom
	1:05 PM	1:20 PM	CONFERENCE WRAP-UP	Grand Ballroom
	1:30 PM	4:00 PM	OPG Consortium (By Invitation)	Seacliff B

BIOS 2019 NF Conference Co-Chairs



Allan Belzberg, MD, Professor of Neurosurgery, Johns Hopkins School of Medicine / Hospital

Dr. Belzberg is the George J Heuer Professor of Neurosurgery at The Johns Hopkins School of Medicine / Hospital. He is the Director of Peripheral Nerve Surgery, and provides care to patients with a variety of nerve pathology. Within the multidisciplinary comprehensive Neurofibromatosis Clinic, he treats patients suffering from a variety of benign and malignant tumors. His expertise in both spinal and peripheral nerve surgery allow him to remove the most challenging nerve tumors and reconstruct both the spine and peripheral nerves. Dr. Belzberg is a clinician scientist interested in neuropathic pain and is the co-director of the Neurosurgery Pain Research Institute with 75 million dollars of philanthropic funding. Dr. Belzberg has an extensive publication record concerning the pathophysiology of painful nerves. His laboratory described a novel

animal model of neuropathic pain that allows the investigator to study both stimulus evoked mechanical hyperalgesia and phenotype change of axons exposed to degenerating axons. He is the PI of the International Schwannomatosis Database currently supported by the Children's Tumor Foundation. Dr. Belzberg is involved in basic science research concerning gene regulation in Schwannomatosis and is also a federal funded investigator developing a biomarker for malignant nerve tumor. Dr. Belzberg is co-director of the multi-disciplinary Nerve Injury Program at the Kennedy Krieger Institute, is a past President of the American Society for Peripheral Nerve and has served as a scientific advisor to a broad spectrum of health care entities including Neurofibromatosis Inc., Axogen, Spinal Kinetics and Medtronic. Dr. Belzberg, born in Montreal Canada, is a graduate of the University of British Columbia, University of Calgary and McGill University. He was awarded a prestigious McLaughlin Foundation Fellowship and travelled to Johns Hopkins where he has remained.



Juha Peltonen, MD, Professor, Institute of Biomedicine, University of Turku, Finland

Juha Peltonen received degrees of MD (1981) and PhD (1985) "Connective tissue in von Recklinghausen's neurofibromatosis" at the University of Turku, Finland. In 1987, he moved to the US to serve as postdoc and later as associate professor, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA. On returning to Finland in 1990, Dr. Peltonen has worked as professor at the Universities of Oulu and Turku. The cellular composition and development of dermal neurofibromas, and skeletal manifestations in NF1 have been the main interests of Dr. Peltonen. More recent approaches include total population analyses of cancer in NF1. Dr. Peltonen's group has established the Finnish Neurofibromatosis Registry which is the first total population based and comprehensive neurofibromatosis registry (JID 135:904-906, 2015). The Finnish

NF Registry has enabled analyses on e.g. the distinctive cancer associations in patients with NF1 (JCO 34:1978-1986, 2016), and elucidation of the natural history of NF1. http://orcid.org/0000-0002-5732-4167 http://www.researcherid.com/rid/C-2817-2008 https://www.researchgate.net/profile/Juha Peltonen2/



Jill Weimer, PhD, Associate Scientist and Senior Director of Therapeutic Development, Sanford Research

Dr. Jill Weimer is a developmental neuroscientist and oversees the management and continued development of the translational arm of Sanford Research in Sioux Falls, South Dakota. She started at Sanford Research in 2009 as an assistant scientist, and her research program focuses on the molecular mechanisms mediating development of the cerebral cortex and how disruption in these processes can lead to a whole host of neural pediatric disorders, including Batten's disease and Neurofibromatosis Type 1. Dr. Weimer grew up in north central Missouri and moved to upstate New York where she received her bachelor's degree and Ph.D. in neuroscience from the University of Rochester. She completed her postdoctoral training in the Neuroscience Research Center at the University of North Carolina in Chapel Hill with a focus on developmental neuroscience.

BIOS

2019 NF Conference Keynote Speakers



Allan Basbaum, PhD, FRS, Professor and Chair, Department of Anatomy, University of California, San Francisco

Born in Montreal, Quebec, Allan Basbaum received his BSc from McGill University and his PhD from the University of Pennsylvania. After postdoctoral research at the University College London and then at the University California San Francisco he was appointed to the faculty of UCSF, where he is presently professor and Chair of the Department of Anatomy. His research addresses the molecular mechanisms that underlie the generation of persistent pain after tissue or nerve injury. Most recently, his laboratory has focused on novel approaches to overcoming the neurological consequences of peripheral nerve damage, by transplanting embryonic cortical inhibitory precursor cells into the spinal cord. He has served as Editor-in-Chief of PAIN, the journal of the International Association for the Study of Pain. He served as Co-Chair of the Steering Committee of the

Intergovernmental Pain Research Coordinating Committee and was recently appointed to the NINDS Council. He is a member of the American Academy of Arts and Sciences, the National Academy of Medicine, the National Academy of Science and is a fellow of the Royal Society in the United Kingdom.



Heike Elisabeth Daldrup-Link, MD, PhD, Department of Radiology, Stanford University

Dr. Heike Elisabeth Daldrup-Link, MD, PhD, is a Professor of Radiology, Director of the Pediatric Molecular Imaging Program, Co-Director of the Cancer Imaging Program and Associate Chair for Diversity in the Department of Radiology at Stanford University. Dr. Daldrup-Link is a physician-scientist with sub-specialization in pediatric oncology imaging. Dr. Daldrup-Link has both uncovered basic science principles for pediatric cancer imaging in an NIH funded-basic science lab and brought the most promising imaging innovations to her patients' bedside.Dr. Daldrup-Link has published more than 160 scientific publications with 8815 citations in scientific journals. Dr. Daldrup-Link's recognitions include the Roentgen Award, the AUR New Investigators Award, the Caffey Award (twice), the UCSF Innovations in Science Award, the Berdon Award (twice), the

Distinguished Investigator Award of the Academy of Radiology Research, Membership in the American Society for Clinical Investigation (ASCI) and Fellow of the American Institute for Medical and Biomedical Engineering (AIMBE), among others.



Stephen C. Groft, PharmD, Senior Advisor to the Director, National Center for Advancing Translational Sciences, NIH

Steve is a Senior Advisor to the Director, National Center for Advancing Translational Sciences (NCATS) at NIH. Previously, he assisted in establishing the Office of Orphan Products Development at FDA in 1982. In 1989 he established a rare diseases initiative at NIH leading to a role as the Director of the Office of Rare Diseases Research (ORDR) at the NIH from 1993-2014. Activities included the development of the Genetic and Rare Diseases Information Center (GARD), the International Rare Diseases Research Consortium (IRDIRC), the International Conference on Rare Diseases and Orphan Drugs (ICORD), the Rare Diseases Clinical Research Network (RDCRN), assisting in the development of the Undiagnosed Diseases Program at NIH's Clinical Center Hospital, and developing common data elements for patient registries and

expanding the International Classification of Diseases XI to include more rare diseases.

His major focus has been on stimulating research with rare diseases and orphan products and developing information for patients, families, health care providers, research investigators, the biopharmaceutical industry, and the public. The emphasis included information about rare diseases, active and completed clinical trials, ongoing research, and patient advocacy groups. He has authored 85 journal articles, book chapters and the co-editor of 2 books on Rare Diseases Epidemiology. He has also made more than 310 presentations on rare diseases.

BIOS

2019 NF Conference Keynote Speakers



Lloyd B. Minor, MD, Dean of the Stanford University School of Medicine

Lloyd B. Minor, MD, is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since December 2012. He is also a professor of Otolaryngology–Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University.

As dean, Dr. Minor plays an integral role in setting strategy for the clinical enterprise of Stanford Medicine, an academic medical center that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Children's Health and Lucile Packard Children's Hospital Stanford. With his leadership, Stanford Medicine has established a strategic vision

to lead the biomedical revolution in Precision Health, a fundamental shift to more proactive and personalized health care that empowers people to lead healthy lives.

Before coming to Stanford, Dr. Minor was provost and senior vice president for academic affairs of The Johns Hopkins University. Prior to his appointment as provost in 2009, Dr. Minor served as the Andelot Professor and director (chair) of the Department of Otolaryngology–Head and Neck Surgery in the Johns Hopkins University School of Medicine and otolaryngologist-in-chief of The Johns Hopkins Hospital.

With more than 140 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders. In the medical community, Dr. Minor is perhaps best known for his discovery of superior canal dehiscence syndrome, a debilitating disorder characterized by sound- or pressure-induced dizziness. He subsequently developed a surgical procedure that corrects the problem and alleviates symptoms.

In 2012, Dr. Minor was elected to the National Academy of Medicine.



Vincent M. Riccardi, MD, MBA, Retired, The Neurofibromatosis Institute

Vincent M. Riccardi, MD, MBA, obtained his undergraduate degree at UCLA (1962), his medical school degree at Georgetown University (1966) and his Internal Medicine training at the University of Pittsburgh (1968). His three-year Genetics Fellowship at the Massachusetts General Hospital was completed in 1972, with an interruption for a U.S. Army stint at the rank of Major in the Medical Corps. In 1973-1975 he was an Assistant Professor in Genetics at the University of Colorado in Denver and an Associate Professor at the Medical College of Wisconsin in Milwaukee from 1975-1977. In all of these positions he had a special interest in Neurofibromatosis, accruing a substantial clinical experience in this regard. He confirmed his commitment to NF by establishing and directing the Baylor NF Program (BNFP) in Houston,

TX, at Baylor College of Medicine and the M.D. Anderson Hospital (1977-1990). In 1990 he moved to Los Angeles, where he became a Clinical Professor of Genetics at UCLA and established The Neurofibromatosis Institute (TNFI). In 1993, he graduated Magna Cum Laude with an MBA from the University of La Verne. In the 47 years since 1972, he has formally engaged over 1,000 persons with NF1 and a similar number less formally. In addition, his laboratory cell culture and biochemistry experience during this time period has contributed substantially to understanding NF1. He has also accumulated an Archive of Biomedical Publications, primarily focusing on NF, in EndNote and an Annotated Bibliography comprising more than 18,000 publications. He continues his professional commitment to NF1 as Director of TNFI and multiple extramural commitments, including the Department of Defense NFRP, CTF and NTAP (External Advisory Committee and Mentor to the Francis S. Collins Scholars).

As regards the CTF meeting presentation on September 24, 2019, he has NO conflicts of interest.

Friday	Septembe	er 20, 2019	
5:00 PM	8:00 PM	REGISTRATION	Grand Ballroom Foyer
5:00 PM	10:00 PM	POSTER SETUP	Pacific H-O
Saturda	y · Septen	nber 21, 2019	
7:00 AM	5:00 PM	REGISTRATION	Grand Ballroom Foyer
7:30 AM	12:00 PM	CLINICAL CARE SYMPOSIUM	Grand Ballroom
		Session Co-Chairs: Scott Plotkin, MD, PhD, <i>Massachusetts General Hospital;</i> Elizabeth Schorry, MD, <i>Cincinnati Children's Hospital;</i> Pamela Trapane, MD, <i>University of Florida</i> <i>Health Jacksonville;</i> Nicole Ullrich, MD, PhD, <i>Boston Children's Hospital</i>	
7:30 AM		Breakfast Available for Symposium Attendees	Grand Ballroom Foyer
8:00 AM	8:05 AM	Welcome and Introduction Scott Plotkin, MD, PhD, Massachusetts General Hospital	
8:05 AM	8:30 AM	Revised Diagnostic Criteria for NF1, NF2, and Schwannomatosis NF1 Eric Legius, MD, PhD, University of Leuven, Belgium	
8:30 AM	9:00 AM	NF2 and Schwannomatosis Scott Plotkin, MD, PhD, <i>Massachusetts General Hospital</i>	
9:00 AM	9:30 AM	Health Supervision for Children with NF1: ACMG/AAP Guidelines David T. Miller, MD, PhD and Nicole Ullrich, MD, PhD, Boston Chilren's Hospital	
9:30 AM	9:40 AM	Strategic Vision for the Neurofibromatosis Clinic Network Heather Radtke, MS, CGC, Children's Tumor Foundation	
9:40 AM	9:55 AM	BREAK	Grand Ballroom Foyer
9:55 AM	10:30 AM	Quality Metrics Project Description and Discussion Justin Jordan, MD, MPH, Harvard Medical School	
10:30 AM	10:55 AM	Clinical Patient Management System of the European Reference Network (ERN) Gareth Evans, MD, University of Manchester, UK	
10:55 AM	11:55 AM	Diagnostic Dilemmas and Case Studies Facilitator: Peter de Blank, MD, MSCE, <i>Cincinnati Children's Hospital</i> Panel: Matthias Karajannis, MD, MS, <i>Memorial Sloan Kettering Cancer Center;</i> Scott Plotkin, MD, PhD, <i>Massachusetts General Hospital;</i> Tena Rosser, MD, <i>Children's Hospital</i> <i>Los Angeles;</i> Elizabeth Schorry, MD, <i>Cincinnati Children's Hospital;</i> Pamela Trapane, MD, <i>University of Florida Health, Jacksonville;</i> Pierre Wolkenstein, MD, PhD, <i>Henri-Mondor</i> <i>Hospital, Paris East University, France</i>	
11:55 AM	12:00 PM	Conclusion Scott Plotkin, MD, PhD, <i>Massachusetts General Hospital</i>	
12:45 PM	1:00 PM	CONFERENCE KICK-OFF	Grand Ballroom
1:00 PM	2:00 PM	KEYNOTE SPEECH 1: From Patients to Patients – And a Whole Lot In-Between Stephen Groft, PharmD, Senior Advisor to the Director, National Center for Advancing Translational Science (NCATS) at NIH	Grand Ballroom
2:00 PM	4:00 PM	SESSION 1: NATURAL HISTORY OF NEUROFIBROMATOSIS	Grand Ballroom
		Session Co-Chairs: Brigitte Widemann, MD, <i>National Cancer Institute;</i> Ana-Maria Vranceanu, PhD, <i>Harvard University;</i> Ethan Lester, PhD, <i>Harvard University</i>	
2:00 PM	2:10 PM	Introduction Brigitte Widemann, MD, <i>National Cancer Institute</i>	

Saturday · September 21, 2019

2:10 PM	2:35 PM	Natural History of the NF1 Cognitive Phenotype Belinda Barton, PhD, <i>Children's Hospital of Westmead, University of Sydney, Australia</i>	
2:35 PM	2:50 PM	<u>Platform</u> : Physical Functioning Outcomes in Children with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibroma (PN) Motor Morbidity on SPRINT: a Phase II Trial of the MEK 1/2 Inhibitor Selumetinib (AZD6244, ARRY-142886; NCT01362803) Pam Wolters, PhD, <i>National Cancer Institute</i>	
2:50 PM	3:05 PM	<u>Platform</u> : Long-term Follow-up of Adult Neurofibromatosis Type 1 Patients Using Whole-body MRI Demonstrates Dynamic Changes in Internal Neurofibroma Size Ina Ly, MD, <i>Massachusetts General Hospital</i>	
3:05 PM	3:20 PM	<u>Platform</u> : Autism Spectrum Disorder and Social Functioning in Children with Neurofibromatosis Type 1: Preliminary Findings from the PANDA Study Jonathan Payne, PsyD, <i>Murdoch Children's Research Institute</i>	
3:20 PM	3:35 PM	<u>Platform</u> : Longitudinal Examination of Attention Problems and Anxiety in Children with Neurofibromatosis Type 1 Kristin Lee, MS, <i>University of Wisconsin-Milwaukee</i>	
3:35 PM	3:50 PM	<u>Platform</u> : Modeling of Long-term NF1 Natural History Data to Predict Plexiform Neurofibroma Growth Cody Peer, PhD, <i>National Cancer Institute</i>	
4:00 PM	4:30 PM	BREAK	Grand Ballroom Foyer
4:30 PM	5:35 PM	SESSION 2: PSYCHOSOCIAL ISSUES OF THE NF PATIENT	Grand Ballroom
		Session Co-Chairs: Ana-Maria Vranceanu, PhD, Harvard University; Ethan Lester, PhD, Harvard University	
4:35 PM	4:55 PM	Virtual Mind-Body Groups Improve Resiliency Factors in Internationally Diverse Patients with NF1, NF2 and Schwannomatosis: Results of Three Randomized Controlled Trials (RCTs) in Adults, Adolescents and Patients Who Are Deaf Ethan Lester, PhD, Harvard University	
4:55 PM	5:10 PM	<u>Platform</u> : Acceptance and Commitment Training (ACT) in Individuals with NF1 and Plexiform Neurofibroma Tumors (PNs) and Chronic Pain: How Important is Treatment Engagement in Daily Life? Staci Martin, PhD, <i>Pediatric Oncology Branch, National Cancer Institute, NIH</i>	
5:10 PM	5:25 PM	<u>Platform</u> : Externalizing Symptoms Drive Social Functioning Difficulties in Children with Neurofibromatosis Type 1 (NF1) Allison del Castillo, <i>Children's National Health System</i>	
5:30 PM	6:30 PM	MENTORING SESSION: "SPEED-DATING WITH THE EXPERTS"	Seacliff AB
6:30 PM	7:30 PM	RECEPTION AND SPECIAL POSTER SESSION FOR NF FORUM ATTENDEES - All Welcome	Pacific H-O
7:45 PM	9:45 PM	Welcome Dinner for NF Forum and NF Conference Attendees	Grand Ballroom
Sunday ·	Septemb	per 22, 2019	
6:45 AM	7:45 AM	NFCN Clinic Coordinator Breakfast (By Invitation Only)	Seacliff C
6:45 AM	7:45 AM	Mentoring Breakfast (RSVP Required)	Seacliff AB
6:45 AM	7:45 AM	Breakfast on Your Own	
7:00 AM	5:00 PM	Registration	Grand Ballroom Foyer
8:00 AM	9:00 AM	KEYNOTE SPEECH 2: The Precision Health Future: Predicting, Preventing and Curing Cancer Lloyd B. Minor, MD, <i>Carl and Elizabeth Naumann Professor, Dean of Stanford University</i> <i>School of Medicine</i>	Grand Ballroom

Sunday ·	Sunday · September 22, 2019						
9:00 AM	12:00 PM	SESSION 3: CANCER	Grand Ballroom				
		Session Co-Chairs: Rebecca Dodd, PhD, <i>University of Iowa;</i> Michael Fisher, MD, <i>Children's Hospital of Philadelphia;</i> Juha Peltonen, MD, PhD, <i>University of Turku, Finland</i>					
9:00 AM	9:25 AM	MPNST: From Beginning to End Luis Parada, PhD, <i>Memorial Sloan Kettering Cancer Institute</i>					
9:25 AM	9:40 AM	<u>Platform</u> : Somatic CRISPR/Cas9 Tumorigenesis Approaches to Study Myeloid Cell Function in MPNST Rebecca Dodd, PhD, <i>University of Iowa</i>					
9:40 AM	9:55 AM	<u>Platform</u> : Pharmacogenomic and Synthetic Lethal Genetic Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors and Malignancies Kyle Williams, PhD, <i>University of Minnesota</i>					
9:55 AM	10:10 AM	Platform: Defining the Mechanisms Underlying Pediatric Brain Tumor Penetrance Nicole Brossier, MD, PhD, Washington University - St. Louis					
10:10 AM	10:15 AM	"Short Burning Questions"					
10:15 AM	10:45 AM	BREAK	Grand Ballroom Foyer				
10:45 AM	11:10 AM	Preclinical and Clinical Studies in NF1-Associated Blood Cancers Kevin Shannon, PhD, University of California San Francisco					
11:10 AM	11:35 AM	Development and Progression of NF1-Associated Peripheral Nerve Sheath Tumors Eduard Serra, PhD, The Institute for Health Science Research Germans Trias i Pujol (IGTP)					
11:35 AM	11:50 AM	<u>Platform</u> : Phase II Trial of the MEK 1/2 Inhibitor Selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) Geraldine O'Sullivan Coyne, MD, <i>National Cancer Institute</i>					
11:50 AM	12:00 PM	Wrap Up and Q&A to All Speakers					
10:45 AM	12:00 PM	SESSION 3B (CONCURRENT): MECHANISMS OF NF2 LOSS-DRIVEN TUMORIGENESIS	Seacliff AB				
		Session Chair: Chunling Yi, PhD, Georgetown University					
10:45 AM	11:05 AM	Mechanistic Underpinnings of TORC1 Activation in NF2 Mutant Tumors Filippo Giancotti, MD, PhD, Anderson Cancer Center					
11:05 AM	11:25 AM	The Hippo-YAP Pathway in Schwannoma – Novel Functions and Therapeutic Implications Joseph Kissil, PhD, <i>The Scripps Institute</i>					
11:25 AM	11:45 AM	NF2 and Cell Contact Regulation of TEAD Stability and Function Barry Gumbiner, PhD, University of Washington/Seattle Children's Hospital					
11:45 AM	12:00 PM	Lipid Signaling in Hippo Pathway Regulation and Cancer Wenqi Wang, PhD, <i>UC Irvine</i>					
12:00 PM	12:40 PM	Lunch	Atrium				
12:45 PM	1:45 PM	KEYNOTE SPEECH 3: Whole Body Imaging of Children with Cancer Heike Daldrup-Link, MD, PhD, <i>Department of Radiology, Stanford University</i>	Grand Ballroom				
1:45 PM	3:15 PM	SESSION 4: DIAGNOSTICS AND IMAGING	Grand Ballroom				
		Session Co-Chairs: Shivani Ahlawat, MD, <i>Johns Hopkins University;</i> Rosalie Ferner, MD, <i>Guy's and St. Thomas' NHS Trust;</i> Michel Kalamarides, MD, PhD, <i>Hôpital Pitié-Salpêtrière, Paris</i>					
1:45 PM	2:10 PM	Quantitative Imaging Analysis in Assessment and Prediction of Tumor Response Wenli Cai, PhD, Massachusetts General Hospital/Harvard University					
2:10 PM	2:25 PM	<u>Platform</u> : Feasibility of Magnetic Resonance-Guided High Intensity Focused Ultrasound for Treatment of Atypical Neurofibromas/Distinct Nodular Lesions Caitlin Tydings, <i>Children's National Medical Center</i>					

Sunday			
2:25 PM	2:40 PM	<u>Platform:</u> Screening Whole Body MRI Using Diffusion Weighted Imaging in Neurofibromatosis Type 1 – Is Intravenous Contrast Medium Necessary? Shivani Ahlawat, MD, <i>The Johns Hopkins University School of Medicine</i>	
2:40 PM	3:10 PM	Cases with Audience Participation: NF1, NF2 and SWN Discussion Lead by Chairs	
3:10 PM	3:40 PM	BREAK	Grand Ballroom Foyer
3:40 PM	4:40 PM	SESSION 4: DIAGNOSTICS AND IMAGING (PART 2)	Grand Ballroom
3:40 PM	4:00 PM	Cranial Nerves Tractography: A Review Michel Kalamarides, MD, PhD, <i>Hôpital Pitié-Salpêtrière Paris</i>	
4:00 PM	4:15 PM	<u>Platform</u> : Non-Ossifying Fibromas in Patients Enrolled in the NCI NF1 Natural History Study Eva Dombi, MD, <i>National Institutes of Health</i>	
4:45 PM	5:05 PM	POSTER ADVERTISEMENTS	Grand Ballroom
4:45 PM	4:55 PM	Basic Science	
4:55 PM	5:05 PM	Clinical Science	
5:05 PM	7:05 PM	POSTER SESSION	Pacific H-0
		Combined Basic and Clinical Science Poster Session. Refreshments to be provided.	
7:00 PM	10:00 PM	REINS Meeting	Marina Room
Monda	y · Septem	ber 23, 2019	
6:45 AM	7:45 AM	Breakfast	Atrium
7:00 AM	7:55 AM	Funding Opportunities (RSVP Required)	Seacliff A
7:00 AM 8:00 AM	7:55 AM 9:00 AM	Funding Opportunities (RSVP Required) KEYNOTE SPEECH 4: Recent Advances in Neurobiology and Management of Neuropathic Pain Allan Basbaum PhD, FRS, Professor and Chair, Department of Anatomy, University of California, San Francisco	Seacliff A Grand Ballroom
		KEYNOTE SPEECH 4: Recent Advances in Neurobiology and Management of Neuropathic Pain Allan Basbaum PhD, FRS, <i>Professor and Chair, Department of Anatomy, University of</i>	
8:00 AM	9:00 AM	KEYNOTE SPEECH 4: Recent Advances in Neurobiology and Management of Neuropathic Pain Allan Basbaum PhD, FRS, <i>Professor and Chair, Department of Anatomy, University of</i> <i>California, San Francisco</i>	Grand Ballroom
8:00 AM	9:00 AM	KEYNOTE SPEECH 4: Recent Advances in Neurobiology and Management of Neuropathic Pain Allan Basbaum PhD, FRS, Professor and Chair, Department of Anatomy, University of California, San Francisco SESSION 5: PAIN AND ITCH Session Co-Chairs: Michael Caterina, MD, PhD, Johns Hopkins School of Medicine; Vanessa Merker, PhD, ENRM Veterans Hospital, Boston; Shawn Kwatra, MD, Johns	Grand Ballroom
8:00 AM 9:00 AM	9:00 AM 11:00 AM	KEYNOTE SPEECH 4: Recent Advances in Neurobiology and Management of Neuropathic Pain Allan Basbaum PhD, FRS, Professor and Chair, Department of Anatomy, University of California, San Francisco SESSION 5: PAIN AND ITCH Session Co-Chairs: Michael Caterina, MD, PhD, Johns Hopkins School of Medicine; Vanessa Merker, PhD, ENRM Veterans Hospital, Boston; Shawn Kwatra, MD, Johns Hopkins University School of Medicine The Role of Mrgprs in Itch Sensation	Grand Ballroom
8:00 AM 9:00 AM 9:00 AM	9:00 AM 11:00 AM 9:30 AM	KEYNOTE SPEECH 4: Recent Advances in Neurobiology and Management of Neuropathic Pain Allan Basbaum PhD, FRS, Professor and Chair, Department of Anatomy, University of California, San Francisco SESSION 5: PAIN AND ITCH Session Co-Chairs: Michael Caterina, MD, PhD, Johns Hopkins School of Medicine; Vanessa Merker, PhD, ENRM Veterans Hospital, Boston; Shawn Kwatra, MD, Johns Hopkins University School of Medicine The Role of Mrgprs in Itch Sensation Xinzhong Dong, PhD, Johns Hopkins School of Medicine Complementary and Integrative Health Therapies for Pain	Grand Ballroom
8:00 AM 9:00 AM 9:00 AM 9:30 AM	9:00 AM 11:00 AM 9:30 AM 10:00 AM	 KEYNOTE SPEECH 4: Recent Advances in Neurobiology and Management of Neuropathic Pain Allan Basbaum PhD, FRS, Professor and Chair, Department of Anatomy, University of California, San Francisco SESSION 5: PAIN AND ITCH Session Co-Chairs: Michael Caterina, MD, PhD, Johns Hopkins School of Medicine; Vanessa Merker, PhD, ENRM Veterans Hospital, Boston; Shawn Kwatra, MD, Johns Hopkins University School of Medicine The Role of Mrgprs in Itch Sensation Xinzhong Dong, PhD, Johns Hopkins School of Medicine Complementary and Integrative Health Therapies for Pain Stephanie Taylor, MD, VA Greater Los Angeles Healthcare System 	Grand Ballroom Grand Ballroom
8:00 AM 9:00 AM 9:00 AM 9:30 AM 10:00 AM	9:00 AM 11:00 AM 9:30 AM 10:00 AM 10:20 AM	 KEYNOTE SPEECH 4: Recent Advances in Neurobiology and Management of Neuropathic Pain Allan Basbaum PhD, FRS, Professor and Chair, Department of Anatomy, University of California, San Francisco SESSION 5: PAIN AND ITCH Session Co-Chairs: Michael Caterina, MD, PhD, Johns Hopkins School of Medicine; Vanessa Merker, PhD, ENRM Veterans Hospital, Boston; Shawn Kwatra, MD, Johns Hopkins University School of Medicine The Role of Mrgprs in Itch Sensation Xinzhong Dong, PhD, Johns Hopkins School of Medicine Complementary and Integrative Health Therapies for Pain Stephanie Taylor, MD, VA Greater Los Angeles Healthcare System BREAK Platform: Sex-Dependent Differences in Pain and Sleep in a Porcine Model of Neurofibromatosis Type 1 	Grand Ballroom Grand Ballroom
8:00 AM 9:00 AM 9:00 AM 9:30 AM 10:00 AM 10:20 AM	9:00 AM 11:00 AM 9:30 AM 10:00 AM 10:20 AM 10:40 AM	 KEYNOTE SPEECH 4: Recent Advances in Neurobiology and Management of Neuropathic Pain Allan Basbaum PhD, FRS, Professor and Chair, Department of Anatomy, University of California, San Francisco SESSION 5: PAIN AND ITCH Session Co-Chairs: Michael Caterina, MD, PhD, Johns Hopkins School of Medicine; Vanessa Merker, PhD, ENRM Veterans Hospital, Boston; Shawn Kwatra, MD, Johns Hopkins University School of Medicine The Role of Mrgprs in Itch Sensation Xinzhong Dong, PhD, Johns Hopkins School of Medicine Complementary and Integrative Health Therapies for Pain Stephanie Taylor, MD, VA Greater Los Angeles Healthcare System BREAK Platform: Sex-Dependent Differences in Pain and Sleep in a Porcine Model of Neurofibromatosis Type 1 Rajesh Khanna, PhD, University of Arizona Platform: Schwann Cells with LZTR1 and SMARCB1 Mutations Have Different Secretomes That Influence Pain 	Grand Ballroom Grand Ballroom
8:00 AM 9:00 AM 9:00 AM 9:30 AM 10:00 AM 10:20 AM 10:20 AM	9:00 AM 11:00 AM 9:30 AM 10:00 AM 10:20 AM 10:40 AM 11:00 AM	 KEYNOTE SPEECH 4: Recent Advances in Neurobiology and Management of Neuropathic Pain Allan Basbaum PhD, FRS, Professor and Chair, Department of Anatomy, University of California, San Francisco SESSION 5: PAIN AND ITCH Session Co-Chairs: Michael Caterina, MD, PhD, Johns Hopkins School of Medicine; Vanessa Merker, PhD, ENRM Veterans Hospital, Boston; Shawn Kwatra, MD, Johns Hopkins University School of Medicine The Role of Mrgprs in Itch Sensation Xinzhong Dong, PhD, Johns Hopkins School of Medicine Complementary and Integrative Health Therapies for Pain Stephanie Taylor, MD, VA Greater Los Angeles Healthcare System BREAK Platform: Sex-Dependent Differences in Pain and Sleep in a Porcine Model of Neurofibromatosis Type 1 Rajesh Khanna, PhD, University of Arizona Platform: Schwann Cells with LZTR1 and SMARCB1 Mutations Have Different Scretomes That Influence Pain Fatima Banine, PhD, Oregon Health & Science University 	Grand Ballroom Grand Ballroom Grand Ballroom Foyer

Monday ·	Septem	ber 23, 2019	
 11:20 AM	11:40 AM	Ferroptosis, Mechanisms and Role in Disease Xuejun Jiang, PhD, <i>Memorial Sloan Kettering Cancer Center</i>	
 11:40 AM	12:00 PM	Harnessing Yap/Taz Signaling Network for Treatment of NF2 Tumors Chunling Yi, PhD, <i>Georgetown University</i>	
12:00 PM	1:00 PM	Lunch on Your Own	
12:00 PM	1:00 PM	Clinical Care Advisory Board Lunch (By Invitation Only)	Seacliff C
1:00 PM	3:00 PM	SESSION 7A (CONCURRENT): CUTANEOUS NEUROFIBROMAS – BENCH TO BEDSIDE	Seacliff AB
		Session Co-Chairs: Jaishri Blakeley, MD, <i>Johns Hopkins University Hospital;</i> Matthew Steensma, MD, <i>Van Andel Research Institute;</i> Eduard Serra, PhD, <i>The Institute for</i> <i>Health Science Research German Trias i Pujol</i>	
1:00 PM	1:25 PM	The Biology of Cutaneous Neurofibroma: Current Understanding and Future Perspectives Lu Le, MD, PhD, <i>University of Texas Southwestern</i>	
1:25 PM	1:50 PM	Cutaneous Neurofibromas: Present, Future Pierre Wolkenstein, MD, PhD, <i>Hopital Henri-Mondor, Creteil, France</i>	
1:50 PM	2:05 PM	<u>Platform</u> : NF1 Patient Missense Variants Predict a Role for ATM in Modifying Neurofibroma Initiation Yanan Yu, Cincinnati Children's Hospital and University of Cincinnati	
2:05 PM	2:20 PM	<u>Platform</u> : The Role of MicroRNA-155 in <i>Nf1</i> Neurofibroma Initiation Jiangiang Wu, PhD, <i>Cincinnati Children's Hospital</i>	
2:20 PM	2:35 PM	<u>Platform</u> : Systematic Longitudinal Evaluation of Phenotype Development in a Swine Model of Neurofibromatosis 1 Katherine White, <i>Sanford Research</i>	
2:35 PM	2:50 PM	<u>Platform</u> : Investigating the Role of NF1+/- Fibroblasts in Neurofibromatosis Type I-Associated Cutaneous Neurofibromas Sara Osum, University of Minnesota	
2:50 PM	3:00 PM	Discussion	
2:00 PM	3:00 PM	SESSION 7B (CONCURRENT): GENETICS OF NF2 AND SCHWANNOMATOSIS	Seacliff AB
		Session Chair: Gareth Evans, MD, St. Mary's Hospital, University of Manchester, UK	
2:00 PM	2:20 PM	Implications of Mosaicism in Neurofibromatosis Type 2 Dorothy Halliday, FRCP, PhD, <i>Oxford University</i>	
2:20 PM	2:35 PM	<u>Platform</u> : Higher Estimates of Mosaicism in <i>De Novo</i> Neurofibromatosis Type 2 Following Increased Use of Next Generation Sequencing Miriam Smith, PhD, <i>University of Manchester</i>	
 2:35 PM	2:50 PM	<u>Platform</u> : A Phase 0 Pharmacodynamic and Pharmacokinetic Study of Everolimus in Vestibular Schwannoma (VS) and Meningioma Patients Matthias Karajannis, MD, MS, <i>Memorial Sloan Kettering Cancer Center</i>	
3:00 PM	3:30 PM	BREAK	Grand Ballroom Foyer
3:30 PM	5:00 PM	SESSION 8: TARGETED GENE EDITING AND GENE THERAPY FOR NEUROFIBROMATOSIS	Grand Ballroom
		Session Co-Chairs: Rajesh Khanna, PhD, University of Arizona; Scott Plotkin, MD, PhD, Massachusetts General Hospital; Aaron Schindeler, PhD, University of Sydney, Australia	
3:30 PM	3:42 PM	Introduction to Gene Therapy Aaron Schindeler, PhD, <i>University of Sydney, Australia</i>	
3:42 PM	3:54 PM	Gene Replacement Therapy for NF2 Marco Giovannini, MD, PhD, UCLA Medical School	

AGENDA Monday · September 23, 2019

monday	L		
3:54 PM	4:06 PM	Genome-Guided Therapeutics for NF1 Bruce Korf, MD, PhD, <i>University of Alabama at Birmingham</i>	
4:06 PM	4:18 PM	Dissecting Pain in NF1 Rajesh Khanna, PhD, <i>University of Arizona</i>	
4:18 PM	4:30 PM	Proactive Engagement of Stakeholders in Developing Clinical Trials for Gene Therapy in NF Patients Scott Plotkin, MD, PhD, <i>Massachusetts General Hospital</i>	
4:30 PM	5:00 PM	Panel Discussion	
5:15 PM	7:15 PM	SESSION 9A (CONCURRENT): BASIC SCIENCE PLATFORM PRESENTATIONS	Seacliff AB
		Session Co-Chairs: David Gutmann, MD, PhD, <i>Washington University, St. Louis;</i> Laura Papi, MD, <i>University of Florence, Italy;</i> Dawn Quelle, PhD, <i>University of Iowa</i>	
5:15 PM	5:30 PM	Neurofibromatosis Type 1: A Sweet Story of Metabolism Rebekah Tritz, MS, Vascular Biology Center, Augusta University	
5:30 PM	5:45 PM	MEK Inhibition Ameliorates Social Behaviour Phenotypes in a Spred1 Knockout Mouse Model for RASopathy Disorders Sarah Borrie, PhD, <i>KU Leuven, Belgium</i>	
5:45 PM	6:00 PM	Macrophage Macropinocytosis: A Potential Target to Attenuate Tumor Vascularization in Neurofibromatosis Type 1 Pushpankur Ghoshal, PhD, <i>Augusta University</i>	
6:00 PM	6:15 PM	Neurofibromin Also Has a GAP-Independent Activity, Acting as a Transcriptional Co- Repressor for Estrogen Receptor-Alpha Eric C. Chang, PhD, <i>Baylor College of Medicine</i>	
6:15 PM	6:30 PM	Screening for ASD Therapies Using a Drosophila Model of NF1 Alex Dyson, MSci, University of Manchester, UK	
6:30 PM	6:45 PM	Modelling the Development of NF1-Associated Malignant Peripheral Nerve Sheath Tumors Using Induced Human Pluripotent Stem Cells and Targeted Temporal Transforming Mutations Garrett Draper, PhD Student, <i>University of Minnesota</i>	
6:45 PM	7:00 PM	Proximity Biotinylation Identifies a Set of Conformation Specific Interactions Between Merlin and Cell Junction Proteins Robert Hennigan, PhD, <i>Cincinnati Children's Hospital</i>	
7:00 PM	7:15 PM	Targeting Protein Translation with Rocaglamide and Didesmethylrocaglamide to Treat NF1 and NF2 Tumors Long-Sheng Chang, <i>Nationwide Children's Hospital / The Ohio State University</i>	
5:15 PM	7:15 PM	SESSION 9B (CONCURRENT): CLINICAL SCIENCE PLATFORM PRESENTATIONS	Grand Ballroom
		Session Co-Chairs: Justin Jordan, MD, PhD, <i>Massachusetts General Hospital;</i> Kaleb Yohay, MD, <i>NYU Langone Medical Center;</i> Sirkku Peltonen, MD, <i>University of Turku, Finland</i>	
5:15 PM	5:30 PM	Prediction of Hearing Prognosis in NF2 Related Vestibular Schwannoma by Genetic Analysis Yu Teranishi, MD, Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Japan	
5:30 PM	5:45 PM	Early Development in Neurofibromatosis 1 (EDEN): Developmental Trajectory and Behavioural Phenotype of Infants with NF1 Shruti Garg, PhD, <i>University of Manchester, UK</i>	
5:45 PM	6:00 PM	A Longitudinal Analysis of Cognitive Predictors of Academic Achievement in Children and Young Adults with Neurofibromatosis Type 1 (NF1) Taryn Allen, PhD, <i>National Cancer Institute</i>	
6:00 PM	6:15 PM	Cognitive Functioning in Adults with NF1: Preliminary Results of a Danish Population-Based Comparison Cohort Study Karoline Doser, MA, Danish Cancer Society	

Monday · September 23, 2019

6:15 PM	6:30 PM	Symptoms, Location and Management of 77 Children with Neurofibromatosis Type 1 Plexiform Neurofibroma in the National Complex Neurofibromatosis Service, Guy's Hospital, UK 2018-2019 Yoshua Collins-Sawaragi, MD, <i>London Children's Hospital</i>
6:30 PM	6:45 PM	Characterizing NF1-Associated Skeletal Manifestations with Single-Cell Resolution and the Effects of MEK Inhibition on Bone Mineral Density in Children with NF1 and Plexiform Neurofibromas Jonathan J Rios, PhD, Texas Scottish Rite Hospital for Children
6:45 PM	7:00 PM	Assessment of Pulmonary Function in Patients with Neurofibromatosis Type 1 and Airway Associated Plexiform Neurofibromas Before and After Treatment with Selumetinib Andrea Gross, MD, National Institutes of Health
7:00 PM	7:15 PM	Validating Measurement Techniques for Cutaneous Neurofibromas in Clinical Trials Scott Plotkin, MD, PhD, Massachusetts General Hospital

Tuesday · September 24, 2019 7:00 AM 8:15 AM **Breakfast on Your Own KEYNOTE SPEECH 5: Perspectives of a "Long-Term" Recklinologist** 9:00 AM 8:15 AM Grand Ballroom Focusing on the Future Vincent Riccardi, MD, Retired, The Neurofibromatosis Institute 9:00 AM 10:00 AM **ORAL POSTER PRESENTATIONS & AWARDS** Grand Ballroom 10:00 AM 11:30 AM **SESSION 10: ANIMAL MODELS** Grand Ballroom Session Co-Chairs: Marco Giovannini, MD, PhD, UCLA School of Medicine; Nancy Ratner, PhD, Cincinnati Children's Hospital Medical Center Modeling NF1 in Drosophila 10:00 AM 10:20 AM James Walker, PhD, Harvard University Platform: Inhibition of the Hippo Pathway in Schwann Cell Lineage Lead to 10:20 AM 10:35 AM Schwannoma Development Zhiguo Chen, PhD, UT Southwestern Medical Center Mouse Models of Neurofibromatosis Type 1 (NF1)-Associated Low- and High-Grade 10:35 AM 10:55 AM Glioma Yuan Zhu, PhD, Children's National Medical Center Development and Validation of a Novel NF2 GEMM to Facilitate Preclinical Studies 10:55 AM 11:15 AM Joseph Kissil, PhD, The Scripps Research Institute Platform: The Role of Neurofibromin in Neurocognitive Impairment, CNS Cell 11:15 AM 11:30 AM Function, and Differentiation in a Porcine Model of Neurofibromatosis Type 1 Vicki Swier Mosher, PhD, Sanford Research 11:30 AM 11:45 AM BREAK Grand Ballroom Foyer 11:45 AM 12:45 PM SESSION 11: SECOND NF HACKATHON OUTCOME Grand Ballroom Salvatore La Rosa, PhD, Children's Tumor Foundation Chief Scientific Officer The winning teams will be presenting their findings during this session. 12:45 PM 1:05 PM **SESSION 12: CONSORTIA UPDATE** Grand Ballroom Michael Fisher, MD, Children's Hospital of Philadelphia, Chair, CDMRP NF Consortium **CONFERENCE WRAP-UP** 1:05 PM 1:20 PM Grand Ballroom 1:30 PM 4:00 PM **OPG Consortium (By Invitation)** Seacliff B


LAST NAME	FIRST NAME	SUFFIX	COMPANY	WORK COUNTRY	WORK STATE
Abaricia	Sarah	R.N, M.S.	Washington University	USA	Missouri
Aguilar-Bonilla	Ana	M.D.	Orlando Health Arnold Palmer Hospital	USA	Florida
Ahlawat	Shivani	M.D.	Johns Hopkins University	USA	Maryland
Akshintala	Vandana	M.D.	National Cancer Institute	USA	Maryland
Allaway	Robert	Ph.D.	Sage Bionetworks	USA	Washington
Allen	Taryn	Ph.D.	Leidos Biomedical Research	USA	Maryland
Amin	Suvina		AstraZeneca Pharmaceuticals	USA	Maryland
Anastasaki	Corina	Ph.D.	Washington University School of Medicine	USA	Missouri
Angulo	Ivan	Ph.D.	Healx	United Kingdom	Cambridgeshire
Anstett	Kara	M.S., CGC	NYU Langone Health	USA	New York
Ayter	Sükriye	Ph.D.	TOBB ETU University	Turkey	
Baker	Laura	M.S., CGC	Nemours Center for Cancer and Blood Disorders	USA	Delaware
Bakker	Annette	Ph.D.	Children's Tumor Foundation	USA	New York
Baldwin	Andrea	R.N., CPNP	Leidos Biomedical Research	USA	Maryland
Banerjee	Jineta	Ph.D.	Sage Bionetworks	USA	Washington
Banine	Fatima	Ph.D.	Oregon Health & Science University	USA	Oregon
Barton	Belinda	Ph.D.	The Children's Hospital at Westmead	Australia	New South Wales
Basbaum	Allan	Ph.D.	University of California San Francisco	USA	California
Beach	Paul		Magaaabuaatta Caparal Haasital	USA	Illinois Maaaaabuaatta
Beauchamp Bedwell	Roberta David	Ph.D.	Massachusetts General Hospital University of Alabama at Birmingham	USA USA	Massachusetts Alabama
	Allan	M.D.	Johns Hopkins Hospital	USA	Maryland
Belzberg	•				
Berger Bielamowicz	Carly Kevin	Student M.D.	Children's National Medical Center Arkansas Children's Hospital	USA USA	District of Columbia Arkansas
Bird-Lieberman	Georgina	IVI.D.	Childhood Tumor Trust	United Kingdom	AIRAIISAS
Blanco	Ignacio	M.D., Ph.D.	HUGTIP	Spain	Barcelona
Bokstein	Felix	M.D., FILD.	Tel Aviv Sourasky Medical Center, Gilbert Israeli Neurofibromatosis Center	Israel	Darociona
Bollag	Gideon	Ph.D.	Research	USA	California
Bora	Naba	Ph.D.	Dept Of Defense, CDMRP	USA	Maryland
Bornhorst	Miriam	M.D.	Children's National Medical Center	USA	District of Columbia
Borrie	Sarah	Ph.D.	KU Leuven, Leuven, BE	Belgium	Vlaams Brabant
Bouley	Stephanie	Ph.D.	Massachusetts General Hospital	USA	Massachusetts
Boyer	John	Ph.D.	AstraZeneca	United Kingdom	Cambridgeshire
Bracegirdle	Sarah		Ashfield Healthcare Communications	United Kingdom	Cheshire
Brainin	Rob		BOD Children's Tumor Foundation	USA	Massachusetts
Brault	Jennifer	M.D.	Vanderbilt University Medical Center	USA	Tennessee
Brems	Hilde	Ph.D.	Center for Human Genetics/ UZ-KU Leuven	Belgium	Vlaams Brabant
Brossier	Nicole	M.D., Ph.D.	Washington University in St. Louis	USA	Missouri
Browder	Vidya	Ph.D.	Children's Tumor Foundation	USA	New York
Cai	Wenli	Ph.D.	Massachusetts General Hospital	USA	Massachusetts
Campen	Cynthia	M.D.	Stanford University	USA	California
Cannon	Ashley	Ph.D.	University of Alabama at Birmingham	USA	Alabama
Carbonell	Amanda	R.N.	National Cancer Institute	USA	Maryland
Carnaby	Jeanne	R.N, M.S.	AstraZeneca	USA	Nebraska
Carnes	Rachel	Student	University of Alabama at Birmingham	USA	Alabama
Castellanos	Elisabeth	Ph.D.	IGTP - CÁMPUS CAN RUTI	Spain	Barcelona
Catasus Segura	Nuria	M.D.	IGTP - CAMPUS CAN RUTI	Spain	Barcelona
Caterina	Michael	M.D., Ph.D.	Johns Hopkins School of Medicine	USA	Maryland
Chagnon	Sarah	M.D.	Children's Specialty Group	USA	Virginia
Chang	Long-Sheng	Ph.D.	Abigail Wexner Research Inst., Nationwide Children's Hospital /	USA	Ohio
			The Ohio State University		
Chang	Eric	Ph.D.	Baylor College of Medicine	USA	Texas
Chen	Zhiguo	M.D., Ph.D.	UT Southwestern Medical Center	USA	Texas
Cho-rohlfsen	Mimi	M.D., Ph.D.	Dermatology specialists	USA	Minnesota
Christen	Jayne	Ph.D.	Leidos	USA	Maryland
Cohen	Tammy		Rimma Sherman, M.D. P.C.	USA	New Jersey
Cohen	Julia	M.D.	Pediatric Oncology Branch/National Institutes of Health	USA	Maryland
Collins-Sawaragi	Yoshua	M.D.	Guy's and St Thomas' NHS Foundation Trust	United Kingdom	Lambeth
Considine	Timothy		Recursion Pharmaceuticals	USA	Utah
Cota	Bruno Cézar	M.D.	Neurofibromatosis Reference Center of the Federal University of Minas Gerais	Brazil	Minas Gerais
Craigen	William	M.D., Ph.D.	Baylor College of Medicine	USA	Texas
Creus	Edgar	M.S.	ICO - IDIBELL Catalan Institute of Oncology	Spain	Barcelona
Crocker	Laura	MD	Ashfield Healthcare Communications	United Kingdom	Cheshire
Cunningham	Tracy	M.D.	AstraZeneca	United Kingdom	Cambridgeshire
Dabscheck	Gabriel	M.D.	Royal Children's Hospital	Australia	Victoria
Daldrup	Heike	M.D., Ph,D.	Stanford University	USA Upited Kingdom	California
Dave Davia Kannan	Foram	Student	University of Plymouth	United Kingdom	Devon
Davis-Keppen	Laura	M.D.	Sanford University of South Dakota School of Medicine	USA	South Dakota
de Blank Dekker	Peter	M.D.	Cincinnati Children's Hospital Medical Center	USA	Ohio Neard Helland
Dekker del Castillo	Saskia	Ctudant	Stichting Neurofibromatose	Netherlands	Noord-Holland
del Castillo	Allison	Student	Children's National Health System	USA	District of Columbia
Derdak	Joanne	R.N., CPNP	National Cancer Institute	USA	Maryland
DeSanto	Jennifer	R.N.	NIH Mayo Clinia	USA	Maryland
Deyle	David	M.D.	Mayo Clinic	USA	Minnesota
Dhamija	Radhika	M.D.	mayo clinic	USA	Arizona
Dobrea	Lavinia	M.S.	AstraZeneca	USA	California
Dodd	Rebecca Rosto Barbara	Ph.D.	University of Iowa Hanover Medical School, Hanover, Cormany	USA	lowa
Doergeloh	Beate Barbara	M.D.	Hanover Medical School, Hanover, Germany	Germany	Lower-Saxony Manuland
Dombi	Eva	M.D.	National Institutes of Health	USA	Maryland
Dompierre	Jessica	R.N.	NIH, National Cancer Institute, Pediatric Oncology Branch	USA	Maryland
Dong	Xinzhong	Ph.D.	Johns Hopkins University School of Medicine	USA	Maryland
Doser	Karoline		Danish Cancer Society	Denmark	København
Doshi	Dipam Garrett	Student	Springworks Therapeutics University of Minnesota	USA USA	California Minnesota
Draper				1154	 MULTIPSOTA


LAST NAME	FIRST NAME	SUFFIX	COMPANY	WORK COUNTRY	WORK STATE
Dufek	Anne	R.N., CPNP	National Institutes of Health	USA	Maryland
Duplain-Laferriere	Frédérique	Student	Université de Sherbrooke	Canada	Québec
Dyson	Alex	Student	University of Manchester	United Kingdom	Greater Manchester
Ehara	Yuko	M.D.	Tottori University Hospital	Japan	Tottori New Verk
Elkin Engel	Zachary Julie	M.D. R.N.	NYU Langone Eye Center Cardinal Glennon Children's Hospital	USA USA	New York Missouri
Engelson	Celia	R.N, M.S.	NYU Langone Health	USA	New York
Evans	D Gareth	M.D., Ph.D.	University of Manchester	United Kingdom	Manchester
Everson	Richard	M.D.	UCLA	USA	California
Farouk Sait	Sameer	M.D.	Memorial Sloan Kettering Cancer Center	USA	New York
Feng	Ying	M.S.	Vivace Therapeutics	USA	California
Fernandez Rodriguez	Juana	Ph.D.	IDIBELL	Spain	Barcelona
Ferner	Rosalie	M.D.	Guy's and St. Thomas' NHS Foundation Trust	United Kingdom	London
Field Finamore	Jeffrey Lauren	Ph.D. R.N, M.S.	University of Pennsylvania/Perelman School of Med Seattle Children's Hospital	USA USA	Pennsylvania Washington
Fisher	Laura	M.S., CGC	Mayo Clinic	USA	Minnesota
Fisher	Carla	111.0., 000	AstraZeneca	United Kingdom	Cambridgeshire
Fisher	Michael	M.D.	Children's Hospital of Philadelphia	USA	Pennsylvania
Fitzgerald	Keely	M.D.	Children's Mercy Hospital	USA	Missouri
Flores	E'Lissa	Ph.D.	Milken Institute	USA	District of Columbia
Franklin	Barbara			USA	New Jersey
Frost	Mick	M.D.	Western Diagnostic Services Laboratory	USA	California
Fukuta	Hirotaka McKinnon	M.D.	The Jikei University School of Medicine Children's Tumor Foundation	Japan USA	Tokyo North Carolina
Galloway Galloway	Tracy		CTF Board of Directors	USA	North Carolina
Gardner	Kathy	M.D.	University of pittsburgh	USA	Pennsylvania
Gazdov	Nikola		Renergy	Bulgaria	,
Geller	Thomas	M.D.	Johns Hopkins All Children's Hospital	USA	Florida
George-Abraham	Jaya	M.D.	Dell Children's Medical Group	USA	Texas
Ghoshal	Pushpankur	Ph.D.	Augusta University	USA	Georgia
Giancotti	Filippo	M.D., Ph.D.	The University of Texas MD Anderson Cancer Center	USA	Texas
Ginn Ginn	Samantha Kevin	Ph.D. M.D.	Children's Medical Research Institute Children's Mercy Hospital	Australia USA	New South Wales Missouri
Giovannini	Marco	M.D., Ph.D.	University of California Los Angeles	USA	California
Glad	Danielle	Student	UWM Psychology Department	USA	Wisconsin
Goetsch	Allison	M.S., CGC	Lurie Children's Hospital and Feinberg School of Medicine	USA	Illinois
Gosline	Sara	Ph.D.	Sage Bionetworks	USA	Washington
Granger	Leslie	M.S., CGC	Randall Children's Hospital at Legacy Emanuel	USA	Oregon
Graup	Lisa		AstraZeneca	USA	Maryland
Greenwood	Robert	M.D.	University of North Carolina School of Medicine	USA	North Carolina
Griffin Grit	Danielle Jamie	Student Student	Children's National Health System Van Andel Institute	USA USA	District of Columbia
Groft	Stephen	Pharm.D.	NCATS	USA	Michigan Maryland
Gros-Louis	Francois	Ph.D.	Universite Laval	Canada	Québec
Gross	Andrea	M.D.	National Institutes of Health	USA	Maryland
Guan	Kun-Liang	Ph.D.	University of California San Diego	USA	California
Gumbiner	Barry	Ph.D.	University of Washington	USA	Washington
Gupta	Punita	M.D.	St Joseph's University Medical Center	USA	New Jersey
Gutmann Hachen	David	M.D., Ph.D.	Washington University School of Medicine	USA USA	Missouri
Hagedorn	Rachel Caroline	M.D. R.N., CPNP	Children's Hospital of Philadelphia/ University of Pennsylvania University of Utah	USA	Pennsylvania Utah
Hahn	Cindy	11.11., 01 11	Texas Neurofibromatosis Foundation	USA	Texas
HAJJAR	FOUAD	M.D.	Advent Health Orlando	USA	Florida
Halliday	Dorothy	M.D., Ph.D.	Oxford University Hospitals NHS Foundation Trust	United Kingdom	Oxfordshire
Handrup	Mette Møller	M.D., Ph.D.	Center of Rare Diseases, Aarhus University Hospital	Denmark	Århus
Harris	Allyse	DI D	Children's Hospital of The King's Daughters	USA	Virginia
Harris	Gordon	Ph.D.	Massachusetts General Hospital	USA	Massachusetts
Harrod Haws	Virginia	M.D.	Dell Children's Medical Center Children's Hospital Colorado	USA USA	Texas Colorado
Haws Heisey	Tina Kara	R.N.	Leido Biomedical Research	USA	Maryland
Hemenway	Molly	R.N., CPNP	Children's Hospital Colorado, Univ of Colorado	USA	Colorado
Hennigan	Robert	Ph.D.	Cincinnati Children's Hospital	USA	Ohio
Hirbe	Angela	M.D., Ph.D.	Washington University in St.Louis	USA	Missouri
Hocking	Matthew	Ph.D.	Children's Hospital of Philadelphia	USA	Pennsylvania
Horvitz	Richard		Chair, CTF Board of Directors	USA	Ohio
Hou	Yang	Ph.D.	National Cancer Institute, NIH	USA Upited Kingdom	Maryland Creater Manabaster
Huson	Susan	M.D.	Retired	United Kingdom	Greater Manchester
lkuta Iloeje	Kunihiro Uche	M.D. M.D.	Nagoya University SpringWorks Therapeutics	Japan USA	Aichi Connecticut
llyas	Mohammed	M.D.	Children's Mercy Hospital	USA	Missouri
Jacobson	Mona	R.N., CPNP	Children's Hospital Colorado/University of Colorado	USA	Colorado
Jiang	Xuejun	Ph.D.	Memorial Sloan Kettering Cancer Center	USA	New York
Jordan	Justin	M.D.	Massachusetts General Hospital	USA	Massachusetts
Joyce	Sarah	Ph.D.	National Health Service UK	United Kingdom	London
Jung	Juliane	Ph.D.	Leibniz Institute on Aging - Fritz Lipmann Institute	Germany	01
Kahler	Melissa		Cincinnati Childrens Hospital	USA	Ohio
Kalamarides	Michel	M.D., Ph.D.	Neurosurgery, Hopital Pitié-Salpetrière	France	
Kallionpää Kamei	Roope Koji	M.S. M.D., Ph.D.	University of Turku Kamei clinic	Finland Japan	Toyama
Karajannis	Matthias	M.D., PII.D. M.D.	Memorial Sloan Kettering Cancer Center	USA	New York
	Gurcharanjeet	M.D.	Alfred I. duPont Hospital for children	USA	Delaware
Kaur					
Kaur Keller	Bryant	Student	University of Minnesota	USA	Minnesota
		Student R.N. R.N.	University of Minnesota CCHMC Children's Tumor Foundation	USA USA USA	Minnesota Ohio

Kenborg Kerr Khalil Khanna Ki Kim Kim Kirk Kirk	Line Megan-Cherise Nashwa Rajesh	Ph.D. Student	Danish Cancer Society	Denmark	København
Kerr Khalil Khanna Ki Kim Kim Kirk	Nashwa	Student		England	
Khalil Khanna Ki Kim Kim Kirk	Nashwa	:	University of Greenwich	England	
Ki Kim Kirk	Rajesh	:	NYU Langone Health - Rusk Rehabilitation	USA	New York
Kim Kim Kirk		Ph.D.	Pharmacology and Neuroscience, University of Arizona	USA	Arizona
Kim Kirk	DongHyuk	Ph.D.	Dana-Farber Cancer Institute/ Harvard Medical School	USA	Massachusetts
Kirk	YooRi	M.S.	Gilbert Family Foundation	USA	Michigan
	Raymond	M.D., Ph.D.	Mount Sinai Hospital	Canada	Ontario
	George	Ph.D.	Astra Zeneca	United Kingdom	Cambridgeshire
Kissil	Joe	Ph.D.	The Scripps Research Institute	USA	Florida
Klein-Tasman	Bonita	Ph.D.	University of Wisconsin-Milwaukee	USA	Wisconsin
Klesse	Laura	M.D., Ph.D.	UT Southwestern	USA	Texas New York
Knight	Pamela	M.S. M.D., Ph.D.	CTF Fukuoka University Hospital	USA	Fukuoka
Koga Kohlmeyer	Monji Jordan	Student	University of Iowa	Japan USA	lowa
Koneazny	Lisa	R.N.	Children's Hospital of WI	USA	Wisconsin
Korf	Bruce	M.D., Ph.D.	The University of Alabama at Birmingham	USA	Alabama
Kwatra	Shawn	M.D.	Johns Hopkins Medicine	USA	Maryland
La Rosa	Salvatore	Ph.D.	Children's Tumor Foundation	USA	New York
Langseth	Abe	Ph.D.	SpringWorks Therapeutics	USA	Maryland
Largaespada	David	Ph.D.	University of Minnesota	USA	Minnesota
Larsson	Alex		University of Minnesota	USA	Minnesota
Lascelles	Karine	M.D.	National Neurofibromatosis Service	United Kingdom	Southwark
			Guys and St Thomas NHS Foundation Trust, London		
Lazaro	Conxi	Ph.D.	Catalan Institute of Oncology (ICO-IDIBELL)	Spain	
Le	Kim My	Student	University of Turku	Finland	_
Le	Lu	M.D., Ph.D.	UT Southwestern Medical Center	USA	Texas
Lee	Beomhee	M.D., Ph.D.	Asan Medical Center	South Korea	
Lee	Kristin	M.S.	UW-Milwaukee	USA	Wisconsin
Legius	Eric	M.D., Ph.D.	UZ Leuven	Belgium	Vlaams Brabant
Lester	Ethan	Ph.D.	Massachusetts General Hospital	USA	Massachusetts
Levin	Becca	Ph.D.	Recursion Pharmaceuticals	USA	Utah
Lewis	Andrea Veetai	M.S., CGC M.D.	Baylor College of Medicine/Texas Children's Hospital oshei children's hospital	USA USA	Texas New York
Li Li	Shiwei	M.D.	Capital Medical University	China	Beijing
Li	Peng	M.D.	Beijing Tian Tan Hospital, Capital Medical University	China	Beijing
Li	Mo	WI.D.	Citicbank	China	Beijing
Lightner	Donita	M.D.	University of Kentucky	USA	Kentucky
Listernick	Robert	M.D.	Northwestern University, Feinberg School of Medicine	USA	Illinois
Liu	Pinan	M.D., Ph.D.	Beijing Tian Tan Hospital	China	Beijing
Lobbous	Mina	M.D.	University of Alabama at Birmingham	USA	Alabama
Long	Ashlee	M.S.	University of Alabama at Birmingham	USA	Alabama
Lopez	Jocelyne	Student	UCSF	USA	California
Lorenzo	Claire	Student	UCSF	USA	California
Ly	Ina	M.D.	Massachusetts General Hospital	USA	Massachusetts
Manso	Simone		CTF Board o	Switzerland	Zürich
Martikkala	Eija	Ph.D.	University of Turku, Institute of Biomedicine	Finland	
Martin Peron	Staci	Ph.D.	National Cancer Institute	USA	Maryland
Maspero	Sally Victor-Felix	R.N. M.D.	CTF-Australia/CHW	Australia	New South Wales
Mautner Mazuelas Gallego	Helena	M.D.	University Medical Center Hamburg-Eppendorf, Dept. of Neurology IGTP	Germany Spain	Barcelona
McDonald	Amy	IVI.D.	Texas Tech University Health Sciences Center	USA	Texas
McGivney	Gavin	Student	University of Iowa	USA	lowa
McMahon	Kate	R.N.	Children's Hospital Colorado	USA	Colorado
Mejia	Luz	M.S.	Canela	USA	Texas
Mejia	Rodrigo	M.D.	MD Anderson Cancer Center	USA	Texas
Merker	Vanessa	Ph.D.	Edith Nourse Rogers Memorial Veterans Hospital	USA	Massachusetts
Merkley	Tricia	R.N.	Seattle Children's Hosptial	USA	Washington
Messiaen	Ludwine	Ph.D.	UAB	USA	Alabama
Miller	David	M.D., Ph.D.	Boston Children's Hospital	USA	Massachusetts
Miller	Douglas	M.D., Ph.D.	University of Missouri School of Medicine	USA	Missouri
Mills	Kristen	Ph.D.	Rensselaer Polytechnic Institute	USA	New York
Minor	Lloyd	M.D.	Stanford University School of Medicine, Dean	USA	California
Mission	Paige	Ph.D.	UW Madison Department of Neurology	USA	Wisconsin
Mo	Juan	Ph.D.	UT Southwestern Medical Center	USA	Texas
Moertel	Christopher	M.D.	University of Minnesota	USA USA	Minnesota North Carolina
Moody	Kristen Chang In	Student	SpringWorks Therapeutics Washington University in St. Louis	USA	Missouri
Moon Moots	Chang-In Paul	M.D.	Vanderbilt University Medical Center	USA	Tennessee
Moran	Jon	Ph.D.	Ashfield Healthcare Communications	United Kingdom	Cheshire
Morin	Caroline	11.0.	Gilbert Family Foundation	USA	Michigan
Morris	Stephanie	M.D.	Washington University	USA	Missouri
Moutal	Aubin	Ph.D.	University of Arizona	USA	Arizona
Nanoo	Seeta	R.N, M.S.	Childrens Hospital Los Angeles	USA	California
Nghiemphu	P. Leia	M.D.	UCLA Neuro-Oncology	USA	California
Nguyen	Thien	Student	Neurology, UCLA Neuro-Oncology	USA	California
Nievo	Marco	Ph.D.	Children's Tumor Foundation	Italy	Siena
Nikrad	Julia	Student	University of Minnesota	USÁ	Minnesota
Nilton	Rezende	M.D.	Federal University of Minas Gerais	Brazil	Minas Gerais
Nishida	Yoshihiro	M.D., Ph.D.	Nagoya University Hospital	Japan	Aichi
O'Sullivan Coyne	Geraldine	M.D., Ph.D.	NIH/National Cancer Institute	USA	Maryland
Oban	Cheri	M.S.	NA	USA	California
Oberlander	Beverly		NF Network	USA	California
Oberlander	Lewis	Ph.D.	Neurofibromatosis Network	USA	California
Oblinger	Janet	Ph.D.	: NCH Research Institute	: USA	: Ohio

LAST NAME	FIRST NAME	SUFFIX	COMPANY	WORK COUNTRY	WORK STATE
Ohashi	Hirofumi	M.D., Ph.D.	Division of Medical Genetics, Saitama Children's Medical Center	Japan	Saitama
Ohden	Lisa	M.S., CGC	Sanford Health	USA	South Dakota
O'Loughlin	Evan	Student	Massachusetts General Hospital	USA	Massachusetts
Oostenbrink	Rianne	M.D., Ph.D.	ErasmusMC	Netherlands	Zuid-Holland
Orden	Tony			USA	California
Orr Osborne	Christina Kimberly	R.N, M.S.	Massachusetts General Hospital University of Kentucky - Neurology Department	USA USA	Massachusetts Kentucky
Ostrow	Kimberly	Ph.D.	Johns Hopkins University	USA	Maryland
Osum	Sara	Student	University of Minnesota	USA	Minnesota
Ota	Arihito	M.D.	Jikei University School of Medicine	Japan	Tokyo
Packer	Roger	M.D.	Children's National Medical Center	USA	District of Columbia
Pan	Yuan	Ph.D.	Stanford University	USA	California
Pancza	Patrice		Children's Tumor Foundation	USA	New York
Panzer	Karin	M.S., CGC	University of Iowa Hospitals and Clinic	USA	lowa
Papi Parada	Laura Luis	M.D., Ph.D. Ph.D.	University of Florence Memorial Sloan Kettering Cancer Center	Italy USA	Firenze New York
Pardej	Sara	Student	University of Wisconsin-Milwaukee	USA	Wisconsin
Patel	Neha	M.D.	University of Wisconsin	USA	Wisconsin
Payne	Jonathan	Ph.D.	Murdoch Children's Research Institute	Australia	Victoria
Peer	Cody	Ph.D.	National Cancer Institute	USA	Maryland
Peltonen	Juha	M.D., Ph.D.	University of Turku	Finland	
Peltonen	Sirkku	M.D., Ph.D.	University of Turku	Finland	
Piccoli Pichard	Giuseppe	Ph.D. M.D.	AstraZeneca National Institutes of Health. NIAMS	USA USA	New York Marvland
Piotrowski	Dominique Corinne Anna	M.D.	Maturial institutes of Health, MAMIS MSKCC	USA	New York
Plotkin	Scott	M.D., Ph.D.	Massachusetts General Hospital	USA	Massachusetts
Pond	Dinel	M.S., CGC	Children's Minnesota	USA	Minnesota
Post	Leonard	Ph.D.	Vivace Therapeutics	USA	California
Powala	Christopher	1	NFlection Therapeutics, Inc.	USA	Pennsylvania
Poyhonen	Minna	M.D., Ph.D.	Dept of Clinical Genetics, Helsinki University Hospital	Finland	
Prada	Carlos	M.D.	Cincinnati Children's Hospital Medical Center	USA	Ohio
Pratilas Pride	Christine Natalie	M.D. Ph.D.	Johns Hopkins University The Children's Hospital at Westmead	USA Australia	Maryland New South Wales
Puccetti	Diane	M.D.	American Family Children's Hospital, University of Wisconsin-Madison	USA	Wisconsin
Quelle	Dawn	Ph.D.	University of Iowa	USA	lowa
Radtke	Heather	M.S., CGC	Medical College of Wisconsin and Children's Tumor Foundation	USA	New York
Rai	Puneet	M.S., CGC	Oregon Health & Science University	USA	Oregon
Ramirez	Erika	R.N.	Washington University	USA	Missouri
Ratner	Nancy	Ph.D.	Cincinnati Children's Hospital	USA	Ohio
Rauen	Kate	M.D., Ph.D.	University of California Davis	USA	California
Reddy	Alyssa	M.D.	University of California San Francisco NCI, NIH	USA USA	California
Reilly Rhodes	Karlyne Steven	Ph.D. M.D., Ph.D.	Indiana University School of Medicine/Riley Hospital for Children	USA	Maryland Indiana
Riccardi	Vic	M.D.	The Neurofibromatosis Institute	USA	California
Rice	Frank	Ph.D.	Integrated Tissue Dynamics LLC	USA	New York
Rios	Jonathan	Ph.D.	Texas Scottish Rite Hospital for Children	USA	Texas
Robinson	J. Elliott	M.D., Ph.D.	California Institute of Technology	USA	California
Röhl	Claas		NF Kinder / NF Patients United	Austria	Wien
Romo	Carlos	M.D.	Johns Hopkins Hospital	USA	Maryland
Rosenbaum Rosenmayr	Thorsten Verena	M.D. Student	Sana Kliniken Duisburg Medical University of Vienna / Department for Pediatrics and Adolescent Medicine	Germany Austria	Wien
Rosser	Tena	M.D.	Children's Hospital Los Angeles	USA	California
Rowe	Ashley		University Hospitals- Rainbow Babies & Childrens	USA	Ohio
Roy	Vincent	Student	Université Laval/LOEX	Canada	Québec
RUBINSTEIN	C DUSTIN	Ph.D.	Biotechnology Center/University of Wisconsin	USA	WI
Rukin Gold	Deborah	M.D.	Rainbow Babies & Children's Hospital	USA	Ohio
Sandelin	Martin	M.D., Ph.D.	AstraZeneca	Sweden	
Sankaran Sarnoff	Hari Herb	M.D.	National Institute of Health Infixion Bioscience, Inc.	USA USA	Maryland California
Sato	Aimee	M.D.	Seattle Children's	USA	Washington
Schatz	Krista	M.S., CGC	Johns Hopkins University Department of Genetic Medicine	USA	Maryland
Schindeler	Aaron	, in the second s	The Children's Hospital at Westmead	Australia	New South Wales
Schorry	Elizabeth (Betty)	M.D.	Cincinnati Children's Hospital Medical Center	USA	Ohio
Seidlin	Mindell	M.D.	Seidlin Consulting LLC	USA	New York
Serra	Eduard	Ph.D.	Program on Hereditary Cancer	Spain	Barcelona
SHAH	NIDHI	M.D.	Penn State Health	USA	Pennsylvania
Shanmuganayagam Shannon	Dhanu Kevin	Ph.D.	University of Wisconsin-Madison University of California San Francisco	USA USA	Wisconsin California
SHARMA	SHEEL	M.D. M.D.	NYU Langone Hospital	USA	New York
Shea, PA-C	Stephanie	:	Children's Hospital Colorado	USA	Colorado
Sheerin	Una-Marie	Ph.D.	Guy's and St Thomas' Hospital NHS Trust	United Kingdom	London
Sherman	Larry	Ph.D.	Oregon Health & Science University	USA	Oregon
Sherman	Rimma	M.D.	Rimma Sherman M.D. P.C.	USA	New Jersey
Shulkin	Oleg	D.N. COND	AstraZeneca Germany GmbH	Germany	Minnest
Siqveland	Elizabeth	R.N., CPNP	Children's - Minnesota	USA United Kingdom	Minnesota
Smith Smith	Miriam Abbi	Ph.D.	University of Manchester Indiana University, School of Medicine	United Kingdom USA	Manchester Indiana
Smith	Katie	R.N.	Children's Hospital of Philadelphia	USA	Pennsylvania
So	Karen	M.D.	AstraZaneca	United Kingdom	Cambridgeshire
Soll	Richard	Ph.D.	WuXi AppTec	USA	Massachusetts
Sommer	Kathy	R.N, M.S.	University of Minnesota	USA	Minnesota
		1	Alvord Brain Tumor Center, University of Washington Medical Center	USA	Washington
Song	Young-Bin	•			
Song Steensma Stevenson	Matthew David	M.D. M.D.	Spectrum Health/Helen DeVos Children's Hospital; Van Andel Institute Stanford University	USA USA	Michigan California

LAST NAME	FIRST NAME	SUFFIX	COMPANY	WORK COUNTRY	WORK STATE
Sun	Daochun	Ph.D.	Memorial Sloan Kettering Cancer Center	USA	New York
Sverak	Pavlina	M.D.	University of Minnesota	USA	Minnesota
Swier Mosher	Vicki	Ph.D.	Sanford Research	USA	South Dakota
Tamula	Mary Anne	M.S.	Leidos Biomedical Research	USA	Maryland
Tang	Tracy	Ph.D.	Vivace Therapeutics	USA	California
Tang	Vivian	M.D.	Royal Manchester Children's Hospital	United Kingdom	Greater Manchester
Taylor	Stephanie	Ph.D.	Veterans Administration	USA	California
Teranishi	Yu	M.D., Ph.D.	Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Japan	Japan	Tokyo
Thain	Lisa	M.D.	Southlake Regional Health Centre	Canada	Ontario
Thain	Emily	M.S., CGC	University Health Network	Canada	Ontario
Thomas	Mary	R.N.	Guy's and St Thomas' Foundation Trust	United Kingdom	London
Thompson	Heather	Ph.D.	California State University, Sacramento	USA	California
Tonsgard	James	M.D.	University of Chicago	USA	Illinois
Traber	Jennifer	MD	Washington University in St. Louis	USA	Missouri
tran	nam	M.D. M.D.	Moffitt Cancer Center UF College of Medicine – Jacksonville	USA USA	Florida District of Columbia
Trapane Tremblay	Pamela Danny	M.S.	CHUM	Canada	Québec
Tritz	Rebekah	M.S.	Augusta University - Vascular Biology Center	USA	Georgia
Truitt	Morgan	Ph.D.	The Salk Institute for Biological Studies	USA	California
Tschiffely	Anna	Ph.D.	Ripple Effect Communications, CDMRP	USA	Maryland
Tsui	Karen	M.D.	Starship Children's Hosptial	New Zealand	marynana
Tumminello	Brad		SpringWorks Therapeutics	USA	Texas
Tydings	Caitlin	M.D.	Children's National Medical Center	USA	District of Columbia
Ullrich	Nicole	M.D., Ph.D.	Boston Children's Hospital	USA	Massachusetts
Uy	Ryan	M.D.	Children's National Medical Center	USA	District of Columbia
Vaassen	Pia	M.D.	Sana Kliniken Duisburg GmbH	Germany	
van Minkelen	Rick	Ph.D.	Erasmus Medical Center	Netherlands	Zuid-Holland
Vassallo	Grace	M.D.	Complex NF1 service	United Kingdom	Manchester
Vasudevan	Harish	M.D., Ph.D.	University of California San Francisco	USA	California
Verma	Sharad	Ph.D.	Johns Hopkins	USA	Maryland
Vishwanathan	Karthick	Ph.D.	AstraZeneca	USA	Massachusetts
Viskochil	David	M.D., Ph.D.	University of Utah	USA	Utah
Vitte	Jeremie	Ph.D.	UCLA	USA	California
Vogt	Daniel	Ph.D.	Michigan State University	USA	Michigan
Vukelj	Simon		Children's Tumor Foundation	USA	New York
Walker	James	Ph.D.	MGH Center for Genomic Medicine	USA	Massachusetts
Wallace	Peggy	Ph.D.	University of Florida	USA	Florida
Wallis	Deeann	Ph.D.	University of Alabama at Birmingham	USA	Alabama
Walsh	Karin	Ph.D.	Children's National Health System	USA	District of Columbia
Walter	Joe	M.D., Ph.D.	AstraZeneca	USA	Maryland
Wang	Xia		Moffitt Cancer Center	USA	Florida
Wang	Wenqi	Ph.D.	University of California, Irvine	USA	California
Watson Weber	Adrienne Mike	Ph.D.	Recombinetics Inc. SpringWorks Therapeutics	USA USA	Minnesota North Carolina
Wegscheid	Michelle	Student	Washington University School of Medicine in St. Louis	USA	Missouri
Weimer	Jill	Ph.D.	Sanford Research	USA	South Dakota
Weiss	Brian	M.D.	Cincinnati Children's Hospital and Medical Center	USA	Ohio
Welling	D. Bradlev	M.D., Ph.D.	Massachusetts Eye and Ear	USA	Massachusetts
Whitcomb	Trish	R.N.	National Cancer Institute	USA	Maryland
White	Jessica		SpringWorks Therapeutics	USA	CT
White	Katie		Sanford Research	USA	South Dakota
Widemann	Brigitte	M.D.	National Institutes of Health	USA	Maryland
Williams	Kyle	Ph.D.	University of Minnesota	USA	Minnesota
Williams	Danaia		Children's Tumor Foundation	USA	New York
Wind Mitchell	Carole	R.N, M.S.	NYU Langone Health	USA	New York
Wirtanen	Tracy	M.S.	Littlest Tumor Foundation	USA	Vermont
Wolf	Heather	M.D.	Kaiser	USA	California
Wolkenstein	Pierre	M.D., Ph.D.	Henri-Mondor Hospital, UPEC, APHP, Créteil, France	France	France
Wolters	Pamela	Ph.D.	National Cancer Institute	USA	Maryland
Woodall	Lesli	M.S.	Medical University of South Carolina, Division of Physician Assistant Studies	USA	South Carolina
Woods	Dennis		Exelixis	USA	Tennessee
Wootton	Michael		NF2 Therapeutics, Inc.	USA	Massachusetts
Wright-Jin	Elizabeth	M.D., Ph.D.	Washington University School of Medicine	USA	Missouri
Wu	Jianqiang	M.D.	Cincinnati Children's Hospital	USA	Ohio
Wu	Natalie	Ph.D.	Cincinnati Children's Hospital and Medical Center	USA	Ohio
Yang	Yang	M.S.	University of Pennsylvania Perelman School of Medicine	USA	Pennsylvania
Yates	Charles	M.D.	Indiana University	USA	Indiana
Yi	Chunling	Ph.D.	Georgetown University Medical Center	USA	District of Columbia New York
Yohay Yoo	Kaleb Hyun Kyoo	M.D.	NYU Langone Health AstraZeneca	USA United Kingdom	Cambridgeshire
Yoshida	Yuichi	M.D.	Tottori University Hospital	•	Tottori
Yoshinaga	Daisuke	M.D.	Kyoto University Hospital	Japan Japan	Kyoto
Yoshinaga	Akiko	M.D.	Kyoto University Hospital	Japan	Kyoto
Young	Lucy	Ph.D.	University of California San Francisco	USA	California
Yu	Yanan	Student	University of California San Francisco	USA	Ohio
Zampelli	Annette	R.N., CPNP	AstraZeneca	USA	Pennsylvania
Zhao	Fu	M.D., Ph.D.	Beijing Tian Tan Hospital	China	Beijing
Zhong	Yan	:	Shenzen Neurofibromatosis (NF) Care Centre	China	Guangdong
Zhou	Jiangbing	Ph.D.	Yale University	USA	Connecticut
Zhou	Chengming		Goverment	China	Beijing
Zhu	Yuan	Ph.D.	Childrens National Medical Center at Washington DC	USA	District of Columbia
			· · · · · · · · · · · · · · · · · · ·		,
Ziegler	Natalie	R.N., CPNP	House Ear Institute	USA	California





CHILDREN'S KUL TUMOR OT FOUNDATION ENDING NF THROUGH RESEARCH

A

2020 NF CONFERENCE JUNE 13 - 16, 2020

SAVE

LOEWS HOTEL | PHILADELPHIA, PA

SPECIAL THANKS TO THE 2019 NF CONFERENCE CHAIRS

Allan Belzberg, MD, Johns Hopkins University

Juha Peltonen, MD, PhD, University of Turku, Finland

Jill Weimer, PhD, Sanford Research

OUR THANKS ALSO TO THE FOLLOWING INDIVIDUALS FOR THEIR EFFORTS:

Scientific Advisory Committee and Program Review Committee Members

Robert Avery, DO Allan Belzberg, MD Peter de Blank, MD Thomas De Raedt, PhD Rebecca Dodd, PhD Eva Dombi, MD Gareth Evans, MD Rosalie Ferner, MD Michael Fisher, MD Filippo Giancotti, MD, PhD Marco Giovaninni, MD, PhD Antonio Iavarone, MD Justin Mordan, MD Michel Kalamarides, MD, PhD Matthias Karajannis, MD, MS Robert Kesterson, PHD AeRang Kim, MD, PhD

Shivani Ahlawat, MD Jaishri Blakeley, MD Michael Caterina, MD, PhD Rebecca Dodd, PhD Gareth Evans, MD Rosalie Ferner, MD Filippo Giancotti, MD, PhD Marco Giovannini, MD PhD David Gutmann, MD, PhD Justin Jordan, MD

Allan Belzberg, MD Matthias Karajannis, MD, MS David Gutmann, MD, PhD Conxi Lazaro, PhD

Joseph Kissil, PhD Bruce Korf, MD, PhD David Largaespada, PhD Conxi Lazari, PhD Lu Le, MD, PhD Eric Legius, MD, PhD Robert Listernick, PhD Alison Lloyd, PhD Victor Mautner, MD, PhD Ludwine Messiaen, PhD Christopher Moertel, MD, PhD Lea Nghiemphu. MD Eric Pasmant, PhD Alejandra Petrilli, PhD Juha Peltonen, MD, PhD Sirkku Peltonen, MD, PhD Scott Plotkin, MD, PhD

Session Chairs

Michael Kalamarides, MD, PhD Rajesh Khanna, PhD Shawn Kwatra, MD Ethan Lester, PhD Vanessa Merker, PhD Laura Papi, MD Juha Peltonen, MD, PhD Sirkku Peltonen, MD, PhD Dawn Quelle, PhD

Mentors (as of 09/10/19)

Staci Martin, PhD Juha Peltonen, MD, PhD Scott Plotkin, MD, PhD

Vincent Riccardi, MD Aaron Schindeler, PhD Elizabeth Schorry, MD Eduard Serra, PhD Lawrence Sherman, PhD Miriam Smith, PhD David Stevenson, MD David Viskochil, MD, PhD Jeremie Vitte, PhD Ana-Maria Vranceanu, PhD Margaret (Peggy) Wallace, PhD Karin Walsh, PsyD Adrienne Watson, PhD Jill Weimer, PHD Brad Welling, MD, PhD Chunling Yi, PhD Yuan Zhu, PhD

Nancy Ratner, PhD Aaron Schindeler, PhD Elizabeth Schorry, MD Eduard Serra, PhD Matthew Steensma, MD Pamela Trapane, MD Ana-Maria Vranceanu, PhD Brigitte Widemann, MD Chunling Yi, PhD Kaleb Yohay, MD

Eduard Serra, PhD Larry Sherman, PhD Nicole Ullrich, MD, PhD Jill Weimer, PhD

SPONSORS

Sponsors, Supporters and Exhibitors

The Children's Tumor Foundation would like to thank:


MEDICAL EDUCATION GRANT AT THE PLATINUM LEVEL



PLATINUM LEVEL SPONSOR



BRONZE LEVEL SPONSOR



EXHIBITOR







